

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

**University of Veterinary Medicine Budapest**

**Doctoral School of Veterinary Science**

**New possibilities in the diagnosis and treatment of canine heartworm disease**

Ph.D. thesis

Zsolt Becker, DVM

Budapest

2022

1 Supervisors  
2  
3  
4 .....  
5 Prof. Károly Vörös, DVM, D.Sc.  
6 Department and Clinic of Internal Medicine  
7 University of Veterinary Medicine Budapest  
8  
9  
10  
11  
12 .....  
13 Prof. Róbert Farkas, DVM, D.Sc.  
14 Department of Parasitology and Zoology  
15 University of Veterinary Medicine Budapest  
16  
17 Consultant  
18  
19  
20  
21 .....  
22 Assoc. prof. Dr. Ferenc Manczur, DVM, PhD  
23 Department and Clinic of Internal Medicine  
24 University of Veterinary Medicine Budapest  
25

1	<b>Table of contents</b>	
2	List of abbreviations .....	5
3	Summary .....	7
4	Összefoglalás .....	10
5	Introduction and aims of the study .....	14
6	1. Serodiagnostic difficulties and possibilities of heartworm disease in regions where both	
7	<i>Dirofilaria immitis</i> and <i>Dirofilaria repens</i> infections occur .....	30
8	<i>Introduction</i> .....	30
9	<i>Materials and methods</i> .....	32
10	<i>Results</i> .....	33
11	<i>Discussion</i> .....	35
12	<i>Conclusions</i> .....	39
13	2. Application of moxidectin and ultrasound-aided injection of melarsomine during the	
14	American Heartworm Society recommended treatment protocol in <i>Dirofilaria immitis</i> infected	
15	dogs.....	40
16	<i>Introduction</i> .....	40
17	<i>Materials and methods</i> .....	43
18	<i>Results</i> .....	47
19	<i>Discussion</i> .....	51
20	<i>Conclusions</i> .....	59
21	3. Description the diagnosis and treatment of a dog with occult heartworm disease .....	60
22	<i>Introduction</i> .....	60
23	<i>History</i> .....	60
24	<i>Physical examination</i> .....	61
25	<i>Diagnostic imaging and routine clinicopathological examinations</i> .....	62
26	<i>Parasitological laboratory examinations</i> .....	62
27	<i>Treatment</i> .....	63
28	<i>Discussion</i> .....	64

1	New scientific results of the thesis .....	66
2	The author's scientific publications.....	84
3	<i>Other publications of the author</i> .....	84
4	Acknowledgements .....	86
5		
6		

## 1 List of abbreviations

2	Ag	antigen
3	AHS	American Heartworm Society
4	ALP	alkaline phosphatase
5	ALT	alanine transaminase
6	An.	<i>Angiostrongylus</i>
7	Ac.	<i>Acanthocheilonema</i>
8	BID	twice daily (bis in die)
9	CI	Blaker 95% confidence interval
10	CT	computer tomography
11	CTA	computer tomographic angiography
12	D.	<i>Dirofilaria</i>
13	DNA	deoxyribonucleic acid
14	ECG	electrocardiogram
15	EDTA	ethylenediaminetetraacetic acid
16	EOD	every other day
17	ELISA	enzyme-linked immunosorbent assay
18	ESCCAP	European Scientific Counsel Companion Animal Parasites
19	ESDA	European Society of Dirofilariosis and Angiostrongylosis
20	FDA	Food and Drug Administration
21	GABA	gamma-aminobutyric acid
22	GI	gastrointestinal
23	HW	heartworm
24	HWs	heartworms
25	HWD	heartworm disease
26	IgG	immunoglobulin G
27	im.	intramuscular
28	inj.	injection
29	L	larval stage
30	LMWH	low-molecular-weight-heparin
31	MDR-1	multi-drug resistance 1
32	mf	microfilaria/microfilariae
33	ML	macrocyclic lactone

1	MLs	macrocyclic lactones
2	PCR	polymerase chain reaction
3	PG	pressure gradient
4	PGP	P-glycoprotein
5	PHT	pulmonary hypertension
6	PTE	pulmonary thromboembolism
7	RCHF	right sided congestive heart failure
8	RPM	round per minute
9	rRNA	ribosomal ribonucleic acid
10	rWSP	recombinant <i>Wolbachia</i> surface protein
11	S.	<i>Spirocerca</i>
12	SAC	Small Animal Clinic
13	sc.	subcutaneously
14	SID	once daily (semel in die)
15	US	ultrasonography
16	UVMB	University of Veterinary Medicine Budapest
17	vmax	maximal velocity
18	WSP	<i>Wolbachia</i> surface protein

## 1 **Summary**

2 Heartworm disease (HWD), caused by *Dirofilaria immitis* is an emerging mosquito-borne  
3 disease in Carnivores, mainly in dogs, and could be found on most of the continents. HWD is  
4 an emerging disease also in Hungary, and several regions are already endemic, especially in the  
5 southern and eastern parts of our country. *Dirofilaria repens* causing mainly subcutan  
6 dirofilariosis also present in Asia and Africa, but not in the Americas. This nematode can also  
7 be found in several middle European countries including Hungary, mainly in similar regions as  
8 *D. immitis*. The concomitant occurrence of these *Dirofilaria* species has special importance,  
9 especially from differential diagnostic aspects, being their treatment also different. Proper  
10 diagnosis, therapy, and prevention of HWD is inevitable for protecting canine patients, and to  
11 inhibit potential human infections which might occasionally be transmitted by infected  
12 mosquitoes. In my thesis, I report on our research related to some new possibilities in the  
13 diagnosis and treatment of canine HWD.

14 *In the first part* of our research, we determined the possibilities of some serodiagnostic methods  
15 in heartworm (HW) infected dogs living in regions where concomitant infections of *D. immitis*  
16 and *D. repens* occur. The VetScan Ag test was used as a model for Ag tests and the PCR assay  
17 served as a standard for the parasitological diagnosis. Sensitivity and specificity were studied  
18 of this Ag test under these conditions. We also aimed to demonstrate if true occult dirofilariosis  
19 could be the explanation for positive Ag tests despite of a negative PCR result of *D. immitis*. In  
20 our cases with occult dirofilariosis, we have applied several, various antigen tests of different  
21 manufacturers for the diagnosis of HWD. These was based on the hypothesis that the chance  
22 for a cross-reaction (false positivity) among *D. immitis* and other helminths (including *D.*  
23 *repens*) is less when more than one HW Ag tests provide positive results from the same blood  
24 sample.

25 Altogether 71 dogs were included retrospectively into the study. These dogs were randomly  
26 selected from dogs arriving for HW screening examinations or with clinical suspect of HWD.  
27 The examination methods included the modified Knott test and in its positivity the polymerase  
28 chain reaction (PCR) methods to identify *D. immitis* and/or *D. repens* infections as well as a  
29 heartworm antigen (Ag) test (VetScan). By using PCR, 26 dogs were found positive only for  
30 *D. immitis* (Group 1), while 21 dogs for both, *D. immitis* and *D. repens* (Group 2). Group 3  
31 included 24 dogs with *D. repens* infection only according to the PCR results. The sensitivity of  
32 the VetScan Ag test for the Group 1 and 2 animals proved to be 97.7% (95% Blaker confidence  
33 interval; CI 89.0% - 99.9%). The specificity of the VetScan Ag test, calculated from the results

1 of Group 3, was found to be 66.7% (95% CI 45.6% - 83.1%), which was lower than that reported  
2 from the USA, where *D. repens* does not occur. In cases when PCR results were positive for *D.*  
3 *repens* but negative for *D. immitis*, occult dirofilariosis was the likely explanation for the  
4 positive *D. immitis* Ag tests. These observations highlight the importance of performing more  
5 Ag tests simultaneously in those areas where both *Dirofilaria* species and occult dirofilariosis  
6 are present. This has special interest when a PCR cannot be performed in the lack of  
7 microfilariae in the peripheral blood or when this technique reveals only the presence of *D.*  
8 *repens*.

9 *In the second part* of my thesis, I present our scientific results related to the treatment of HWD.  
10 The standard therapy of HWD is recommended by the American Heartworm Society (AHS)  
11 which is effective and accepted internationally. During our research, we have modified and  
12 complemented the AHS protocol with some additional new medications and therapeutic  
13 measures to decrease the possible side-effects and to further improve the efficacy and outcome  
14 of the AHS therapeutic procedure. For these purposes, moxidectin was newly used as part of  
15 the complex therapeutic protocol. Probiotics were added to the application of doxycycline, in  
16 order to decrease the potential gastrointestinal side-effects of this antibacterial drug. The  
17 patients were sedated with butorphanol before the intramuscular application of the melarsomine  
18 injection into the paralumbar musculature. The exact place of the needle was determined with  
19 the help of ultrasonography, and the potential local complications were also followed with this  
20 imaging method.

21 The AHS complex therapeutic protocol modified and complemented as described above was  
22 used in 44 heartworm-positive canine patients. Microfilaremic dogs were pretreated with  
23 prednisolone and clopidogrel for one week before the first moxidectin application to avoid  
24 potential adverse (shock-like) reactions which could be caused by the dying microfilariae.  
25 Moxidectin was applied locally as spot-on solution, on the 1<sup>st</sup>, 30<sup>th</sup>, 60<sup>th</sup>, and 90<sup>th</sup> therapeutic  
26 days. On the 1<sup>st</sup> day, dexamethasone and chloropyramine were used to avoid potential adverse  
27 effects mentioned above. During the 1<sup>st</sup>-28<sup>th</sup> days, doxycycline 10 mg/kg BID was given with  
28 probiotics. Adult heartworms were treated with melarsomine on the 60<sup>th</sup>, 90<sup>th</sup> and 91<sup>st</sup> days.  
29 Butorphanol and dexamethasone were given just before melarsomine injections. The depth of  
30 the intramuscular injection site was determined by ultrasound examination of the lumbar  
31 muscles. From the 60<sup>th</sup> day, dalteparin was applied for 10 days to decrease the chance of  
32 pulmonary thromboembolism, elicited by the destroyed adult heartworms.



1 Moxidectin did not cause adverse (shock-like) reactions, even in microfilaremic dogs. This  
2 might be also due to pretreating these dogs with prednisolone and clopidogrel before  
3 moxidectin application. By using moxidectin instead of ivermectin, a complete healing of each  
4 HWD patients was achieved and no death occurred even in severe (Clinical stage 3) cases,  
5 which results are remarkably better compared to previous studies regarding the outcome of  
6 therapy. The partial adulticide effect of moxidectin might have been added to that of  
7 melarsomine, which can be an explanation for the favorable (100%) recovery rate of our  
8 patients. Gastrointestinal side effects of doxycycline were observed only in 3 (6%) dogs, that  
9 healed after symptomatic therapy and by lowering the initial 10 mg/kg BID dose to 5 mg/kg  
10 BID. Transient anorexia and diarrhea were found in one (2%), as well as coughing and mild  
11 dyspnea in one (2%) animal as systemic post-therapeutic complications of melarsomine. These  
12 gastrointestinal side effects of doxycycline treatment were remarkably lower compared to  
13 previous studies, possibly due to probiotics supplementation. Butorphanol provided satisfactory  
14 sedation and analgesia during and after melarsomine injection. Ultrasonography was  
15 successfully applied to determine the location of the injection needle for melarsomine injection.  
16 This method allowed the follow-up of the course of local side effects which were milder  
17 compared to literary data. Namely, no local side effects were observed in 13 (30%) dogs, mild  
18 local side effects occurred in 29 (66%) patients, and severe local swelling only in 2 (4%) cases.  
19 All dogs recovered clinically by the 120<sup>th</sup> day and no microfilaraemia was seen that time by  
20 using the modified Knott test in 33/44 patients. A HW antigen test performed in 33/44 animals  
21 on the 271<sup>st</sup> day was also negative in all cases.

22 *The third part* of my thesis includes a case report on a dog with true occult dirofilariosis which  
23 caused severe clinical symptoms, that has not been published previously in Hungary. This case  
24 report is also an example of the diagnostic work-up and therapeutic management of severe  
25 HWD caused by occult dirofilariosis with special regard for applying several Ag tests in these  
26 cases. The latter has never been published as to our search through the international literature.

27

## 1 Összefoglalás

2 A kutyák szívférgessége, amelyet a *Dirofilaria immitis* idéz elő, egyre gyakoribbá váló,  
3 szúnyogok közvetítette betegség ragadozóknak - különösen kutyákban - amely megtalálható a  
4 legtöbb kontinensen. Európában a szívférgesség korábban a mediterrán déli régiókban fordult  
5 elő, de manapság már terjed északi irányba is. Ez a tendencia elsősorban a globális  
6 felmelegedésnek tudható be, ami kedvező a szúnyog vektorok számára, de részben betudható a  
7 kutyákkal történő, gyakoribb nemzetközi utazásoknak is. Napjainkban a szívférgesség egyre  
8 gyakoribbá válik Magyarországon is, és számos régió már endémiásnak mondható, különösen  
9 hazánk déli és keleti területein. A *Dirofilaria repens* elsősorban a bőr alatti dirofilariosist idézi  
10 elő, és szintén jelen van Ázsiában, valamint Afrikában, azonban nem található meg az amerikai  
11 földrészen. Ez a féreg számos közép európai országban, köztük Magyarországon is jelen van,  
12 főképpen azokon a területeken, ahol a *D. immitis* is fellelhető. A két parazita együttes  
13 előfordulásának különleges jelentősége van, főképpen differenciál diagnosztikai  
14 szempontokból, mivel a gyógykezelésük is különböző. A szívférgesség megfelelő  
15 diagnosztikája, fertőzöttség esetén a terápiája, illetve a megelőzése nélkülözhetetlen ahhoz,  
16 hogy a kutyákat megvédjük a betegség következményeitől, és azért is, hogy meggátoljuk a  
17 potenciális humán fertőződéseket, amelyek alkalmanként előfordulhatnak a fertőzött  
18 szúnyogok közvetítése révén. Értekezésemben beszámolok néhány új lehetőségről a  
19 szívférgesség megállapításának és gyógykezelésének kapcsán végzett kutatómunkánk során.

20 *Kutatásunk első részében* olyan szívféreggel fertőzött kutyákban alkalmaztuk a parazitológiai  
21 diagnosztikai módszereket, amelyek olyan területekről származtak, ahol a *D. immitis* és a *D.*  
22 *repens* együttesen fordul elő. A kutatás indokát elsősorban az jelentette, hogy nem találtunk  
23 információkat a *D. immitis* antigéntesztek értékeléséről az ilyen régiókban élő kutyákra  
24 vonatkozóan. Modellként a VetScan antigéntesztet használtuk az antigéntesztek közül, és a  
25 PCR-eljárás szolgáltatta a parazitológiai diagnózis standardját. A szenzitivitás és a specificitás  
26 meghatározására ilyen feltételek mellett került sor az említett antigéntesztre vonatkozóan.  
27 Szintén szándékunkban állt annak tanulmányozása, miszerint a tényleges okkult dirofilariosis  
28 lehet-e a magyarázata a pozitív eredményt mutató szívférgesség antigénteszteknek azokban az  
29 esetekben, amikor a *D. immitis* PCR eredménye negatív volt, amelyet időnként a saját klinikai  
30 praxisunkban, korábban tapasztaltunk. Ilyenkor nem találhatók mikrofiláriák a perifériás  
31 vérben a szívférgesség során, a szervezet immunológiai védekező reakciójának következtében,  
32 és emiatt a kimutatásukra szolgáló Knott-teszt negatív eredményt ad. Az okkult szívférgesség  
33 eseteiben többféle, különböző gyártótól származó antigéntesztet vettünk igénybe a

1 szívférgesség diagnózisának céljából. Ezt arra a hipotézisünkre alapoztuk, miszerint a tévesen  
2 pozitív keresztreakciók esélye a *D. immitis* és más férgek (köztük a *D. repens*) között kisebb,  
3 amennyiben több antigénteszt is pozitív eredményt ad ugyanabból a vérmintából.

4 Összesen 71 kutyát vontunk be randomszerűen a kutatásba azok közül, amelyek a szívférgesség  
5 felderítésére szolgáló szűrővizsgálatokra vagy pedig a szívférgesség klinikai gyanújával  
6 érkeztek. A vizsgálati módszerek magukban foglalták a módosított Knott-tesztet, ennek  
7 pozitivitása esetén a PCR-vizsgálatot a *D. immitis* és/vagy a *D. repens* fertőzések azonosítására,  
8 valamint a fent említett szívféreg antigéntesztet. A PCR-eljárás során 26 kutya bizonyult csupán  
9 *D. immitis* pozitívnak (1-es csoport), míg 21 kutyában egyidejű *D. immitis* és *D. repens* fertőzést  
10 mutattunk ki (2-es csoport). A 3. csoport 24 olyan kutyát foglalt magában, amelyekben csak *D.*  
11 *repens* fertőzés fordult elő a PCR-eredmények alapján. A VetScan antigénteszt szenzitivitását  
12 az 1-es és a 2-es csoport adataiból határoztuk meg, és ez 97,7%-nak bizonyult (95%-os Blaker-  
13 féle konfidencia intervallum; KI 89,0% - 99,9%). A VetScan antigénteszt specificitását a 3-as  
14 csoport eredményeiből számoltuk ki, ami 66,7%-nak bizonyult (95% KI 45,6% - 3,1%), Ez az  
15 érték alacsonyabb azokhoz a tanulmányokhoz képest, amelyeket az Amerikai Egyesült  
16 Államokban végeztek, ahol a *D. repens* nem fordul elő. A pozitív *D. repens* és egyúttal negatív  
17 *D. immitis* PCR-eredmények esetén az okkult dirofilariosis volt a valószínű magyarázatunk a  
18 pozitív *D. immitis* antigénteszteket illetően. Ezek a megfigyelések megvilágítják a jelentőségét  
19 annak, hogy egyidejűleg célszerű több antigéntesztet igénybe venni azokban a régiókban, ahol  
20 mindkét *Dirofilaria*-faj jelen van, és az okkult dirofilariosis egyaránt előfordul. Ennek különös  
21 jelentősége van, ha a PCR-vizsgálat nem végezhető el a microfilaraemia hiányában, vagy pedig  
22 csak a *D. repens* jelenléte mutatható ki.

23 *Az értekezésem második részében* bemutatom azokat az új tudományos eredményeinket,  
24 amelyek a szívférgesség gyógykezeléséhez kapcsolódnak. A szívférgesség standard terápiáját  
25 az Amerikai Szívférgesség Társaság (American Heartworm Society, AHS) ajánlása alapján  
26 végzik világszerte, amely hatékony módszernek mondható. Ez az összetett terápiás protokoll  
27 magában foglal egy makrociklikus laktont (napjainkig az ivermektint) a mikrofiláriák, valamint  
28 az L3 és az L4 lárvák elpusztítása céljából, a doxiciklint a szimbionta *Wolbachia*  
29 baktériumokkal szemben és az adulticid hatású melarzomin-dihidrokloridot. Ugyanakkor  
30 mellékhatások és komplikációk egyaránt előfordulhatnak ezeknek a gyógyszereknek a  
31 használatakor. A kutatásunk során módosítottuk és kiegészítettük az AHS protokollt néhány  
32 további, ebből a szempontból újonnan alkalmazott gyógykezelési eljárással, annak érdekében,  
33 hogy csökkentjük a mellékhatásokat, és tovább fokozzuk a terápia hatékonyságát, illetve

1 javítsuk a betegség kimenetelét. Ebből a célból, makrociklikus laktonként a moxidektint  
2 használtuk az ivermektin helyett, tudomásunk szerint elsőként a szakirodalomban, ami a  
3 moxidektin alkalmazását illeti, a szívférgesség komplex terápiájának részeként. A doxiciklin  
4 kezelés mellé probiotikumokat adtunk annak érdekében, hogy csökkentsük e gyógyszer  
5 potenciális gastrointestinalis mellékhatásait. Pácienseinket butorfanollal bódítottuk a  
6 melarzomin injekció applikációja előtt. Az injekciós tű pontos helyét ultrahangvizsgálat  
7 segítségével állapítottuk meg paralumbalis izmokban, és ezzel a módszerrel követtük nyomon  
8 a potenciális helyi szövődeményeket is.

9 Az AHS komplex terápiás protokoll fent leírtaknak megfelelően módosított és kiegészített  
10 változatát alkalmaztuk 44 szívféreg-pozitív kutyában. A mikrofiláriás pácienseknek előzetesen  
11 prednizolont és klopidogrélit adtunk egy hétig, az első moxidektin kezelés előtt, a potenciális  
12 adverz (sokkszerű) reakciók megelőzésére, ami a mikrofiláriák pusztulásakor fordulhat elő. A  
13 moxidektint az 1., a 30., a 60. és a 90. terápiás napon, helyileg applikáltuk, rácseppentő oldat  
14 formájában. Az első napon dexametazont és kloropiramint kaptak azok a kutyák, amelyek  
15 perifériás vérében mikrofiláriák voltak kimutathatók, annak érdekében, hogy elkerülhessük a  
16 potenciális adverz (sokkszerű) reakciókat. Az első 28 napban doxiciklint alkalmaztunk 10  
17 mg/kg/12h dózisban, probiotikum kiegészítés mellett. A felnőtt szívférges ellen melarzomint  
18 injektáltunk a 60., 90 és a 91. napokon. A butorfanolt és a dexametazont közvetlenül a  
19 melarzomin injekció előtt adtuk be a microfilaraemiás kutyáknak, a fent említett adverz  
20 reakciók elhárítására. Az intramuscularis injekciók helyét és mélységét ultrahangvizsgálattal  
21 határoztuk meg a paralumbalis izomzatban. A 60. naptól dalteparint adtunk 10 napig, hogy  
22 csökkentsük a pusztuló adult szívférges okozta thromboembolia veszélyét a tüdőben.

23 A moxidektin nem idézett elő adverz reakciókat még a mikrofiláriás kutyákban sem. Ehhez  
24 hozzájárulhatott az is, hogy az ilyen pácienseinket prednizolonnal és klopidogréllel előkezeltük  
25 a moxidektin applikációja előtt. A moxidektinnek az ivermektin helyetti alkalmazása során  
26 teljes gyógyulást tudtunk elérni valamennyi szívférges kutyában, és nem fordult elő elhullás,  
27 még a súlyos (3. klinikai) stádiumba sorolt pácienseknél sem. Ezek az eredmények  
28 kedvezőbbek az eddigi tanulmányokban közöltekhez képest, a terápia kimenetelét illetően. A  
29 moxidektin részleges adulticid jellege is hozzájárulhatott a melarzomin hatásához, ami az egyik  
30 magyarázata lehet pácienseink kedvező (100%-os arányú) gyógyulásának. A doxiciklin  
31 gastrointestinalis mellékhatásait csupán 3 kutyában (6%) figyeltük meg, amelyek a tüneti  
32 kezelés után és a kezdeti 10 mg/kg/12h adag 5 mg/kg/12h csökkentésére gyógyultak. Átmeneti  
33 étvágytalanság és hasmenés fordult elő egy (2%) kutyában, valamint köhögés és enyhe

1 nehezített légzés egy másik (2%) kutyában, mint a melarzomin szisztémás poszterápiás  
2 komplikációja. A doxiciklin gastrointestinalis mellékhatásai lényegesen ritkábban fordultak  
3 elő, és enyhébbek voltak a korábbi tanulmányokhoz képest, feltehetően a probiotikumokkal  
4 való kiegészítésnek tulajdoníthatóan. A butorfanol megfelelő bódítást és fájdalomcsillapítást  
5 biztosított a melarzomin injekció beadásakor és azt követően. Az ultrahangvizsgálatot sikeresen  
6 alkalmaztuk az injekciós tű helyének meghatározására a melarzomin injekció applikációja  
7 során. Ez a módszer lehetővé tette a helyi mellékhatások nyomon követését is, amelyek  
8 enyhébbek voltak a szakirodalmi adatokhoz képest. Eszerint nem volt mellékhatás 13 (30%)  
9 kutyában, enyhe helyi mellékhatások mutatkoztak 29 (66%) páciensben és súlyos helyi  
10 duzzanat mindössze 2 (4%) esetben alakult ki. Valamennyi kutya klinikailag gyógyult volt a  
11 120. napon, és nem voltak mikrofiláriák kimutathatók ebben az időben a módosított Knott-  
12 tesztel vizsgált 33/44 páciensünkben. Szívférgesség antigéntesztre 33 páciensünkben került sor  
13 az összesen 44 kutyából a 271. napon, amely valamennyi esetben negatívnak bizonyult.

14 *Az értekezésem harmadik része egy esetismertetést foglal magában egy valódi okkult*  
15 *dirofilariosis okozta, súlyos betegségben szenvedő kutyáról. Az elsődleges célja ennek az*  
16 *esetismertetésnek az volt, hogy demonstráljuk a fő klinikai tüneteket, valamint a diagnosztikai*  
17 *és terápiás módszerek lehetőségeit a valódi okkult dirofilariosis során, amelyről korábban még*  
18 *nem publikáltak Magyarországon. Ez az esetismertetés egyúttal példát szolgáltat a*  
19 *diagnosztikai és gyógykezelési tevékenység lehetőségeire az okkult dirofilariosis által okozott*  
20 *súlyos szívférgesség eseteiben, különös tekintettel több antigénteszt egyidejű*  
21 *alkalmazhatóságára. Tudomásunk szerint ez utóbbiról még nem jelent meg közlemény, a*  
22 *nemzetközi szakirodalom áttekintése alapján.*

23

# 1 **Introduction and aims of the study**

## 2 *Etiology and occurrence of the disease*

3 Heartworm disease (HWD), caused by *Dirofilaria immitis* is an emerging mosquito-borne  
4 disease in carnivores, mainly in dogs, and could be found on most of the continents (McCall et  
5 al. 2008, Morchón et al. 2012a, Simón et al. 2012, Morchón et al. 2022). This vector-borne  
6 species belongs to the Nematoda phylum, Spirurida order, Onchocercidae family, *Dirofilaria*  
7 genus and subgenus. The main host of *D. immitis* is the dog, however it can be found in other  
8 carnivores as well e.g., cats, ferrets, wild carnivores, and red pandas (van Zeeland and  
9 Schoemaker 2022). The disease also has zoonotic properties, but it is abortive in the human  
10 host, therefore no mature parasites develop, or microfilariae occur (Pampiglione et al. 1995,  
11 Kassai 2003, 2011). The larvae in people migrate into the lung, dying there and causing benign  
12 nodular lesions, only with mild clinical signs. These alterations have differential diagnostic  
13 properties during radiologic and/or CT-examinations (Morchón et al. 2012a, Simón et al. 2012,  
14 Malik et al. 2016). The spreading of canine HWD could also predict that the number of human  
15 cases will also increase in endemic regions (Laidoudi et al. 2021, Mendoza-Roldan et al. 2021,  
16 Miterpáková et al. 2022).

17 In Europe, HWD was formerly found at the tropical and in the south Mediterranean regions  
18 e.g., Spain, Portugal, Greece, France, and Turkey. Its spreading towards the North is due to  
19 global warming being favorable for the mosquito vectors (ESDA Guideline 2017, Drake and  
20 Wiseman 2018, ESCCAP Guideline 05. 2019, Farkas et al. 2020, Fuehrer et al. 2017) and to  
21 the increase in international travelling with dogs, HWD appeared in middle and Eastern Europe  
22 e.g., Serbia, Croatia, Czech Republic, Slovakia, and Romania. The unrecognition of the disease  
23 can also be a reason of its spreading (Genchi et al. 2005, Morchón et al. 2012a, Simón et al.  
24 2012, Capelli et al. 2018, Farkas et al. 2020, Fuehrer et al. 2021, Morchón et al. 2022). In  
25 Hungary, wild carnivores i.e., red foxes and golden jackals might also play a role in the  
26 transmission of HWD (Tolnai et al. 2014).

27 In Hungary, the first occurrence of HWD was diagnosed in imported dogs, and their necropsy  
28 findings were published (Boros et al. 1982). Vörös et al. (2000) reported on an imported dog  
29 infected with *D. immitis*, describing the clinical signs and pathology of the disease. The first  
30 autochthonous case was diagnosed in 2007 and described by Jacsó et al. (2009). In the following  
31 years, increasing number of indigenous cases occurred in the country and HWD became

1 endemic in Southern and Eastern Hungary (Farkas et al. 2014, Bacsadi et al. 2016a, Bacsadi et  
2 al. 2016b, Trájer et al. 2016, Farkas et al. 2020).

3 Other nematodes being important in the differential diagnosis of heartworm disease are *D.*  
4 *repens* (Onchocercidae family, *Dirofilaria* genus, *Nochtiella* subgenus), rarely *Spirocerca lupi*  
5 (Spirucercidae family), *Angiostrongylus vasorum* (Rhabditida order, Angiostrongylidae  
6 family), and *Acanthocheilonema reconditum* (Onchocercidae family, *Acanthocheilonema*  
7 genus) (Manfredi 2001, Kassai 2003, 2011). Occurrence of *An. vasorum* has been reported in  
8 dogs several times in Hungary (Majoros et al. 2010, Csöndes et al. 2015, Schnyder et al. 2012,  
9 Nemes et al. 2016). There are publications on *Spirocerca lupi* from our country as well (Bokori  
10 et al. 1956, Széll et al. 2001, Psáder et al. 2017).

11 *D. repens* causing mainly subcutan dirofilariosis also present in Asia and Africa, but not in the  
12 Americas (Simon et al. 2012, Jacsó 2014, Genchi and Kramer 2017, Capelli et al. 2018). *D.*  
13 *repens* is known in Hungary, and in several middle European countries (Fok et al. 1998, Széll  
14 et al. 1999, Jacsó and Fok 2006, Spasojevic Kosic et al. 2012, Jacsó 2014, Cabanová et al. 2015,  
15 Härtwig et al. 2015, Ciuca et al. 2016a, Ciuca et al. 2016b, Fuehrer et al. 2016, Farkas et al.  
16 2020). In Hungary, the first autochthonous case of was published at the end of the 1990's (Fok  
17 et al. 1998). However, the occurrence of the disease was already suspected from 1950 (Kotlán  
18 1951). Clinical appearance, as well as potential therapeutic and preventive methods regarding  
19 *D. repens* infections have been published by the European Society of Dirofiariosis and  
20 Angiostrongylosis (ESDA) (ESDA Guideline 2017).

21

## 22 *Life cycle of D. immitis*

23 The life cycle of *Dirofilaria immitis* is indirect, which takes about 6-9 months (Hoch and  
24 Strickland 2008a, Bowman and Atkins 2009, Farkas and Vörös 2015, ESDA Guideline 2021,  
25 ESCCAP Guideline 05 2019). The matured female releases microfilaria (mf) into the host's  
26 blood stream of the infected dog and the mf must enter a suitable female mosquito during blood  
27 sucking (Manfredi et al. 2007, Nelson et al. 2020). The main vector species in Hungary are  
28 *Aedes vexans*, *Anopheles maculipennis* and *Culex pipiens* (Jacsó 2014). Other mosquito species  
29 can also be vectors for the disease (Nelson et al. 2020). In the mosquito, the microfilaria  
30 develops into a first-stage larva (L1) and after 2 molts becomes the infective third-stage larva  
31 (L3) (Hoch and Strickland 2008a, Bowman and Atkins 2009). The temperature of the  
32 environment greatly influences the length of its development. The fastest development takes

1 about 10-14 days at 27 °C. Below 14 °C, the transformation stops, however, if the temperature  
2 will rise, the larva develops further (Bowman and Atkins 2009, Nelson et al. 2020). The fully  
3 grown L3 will migrate to the labium of the mosquito from where - during the blood-sucking of  
4 the vector – it will get in a drop of hemolymph on the skin of the host and migrate into the  
5 subcutaneous tissue via the puncture of the infected mosquito (Manfredi et al. 2007, Nelson et  
6 al. 2018). It is interesting, that there is a natural inhibiting factor to decrease the number of  
7 infective larvae in the vector. The immune system of the mosquito recognizes the developing  
8 larvae as an antigen, and can injure the cuticle of the mf, therefore it cannot molt to L3  
9 (Chandrasekharan et al. 1994, Manfredi et al. 2007, Simón et al. 2012).

10 The 3rd molt begins on day 3 in the host. By day 21, most of fourth larvae (L4) have migrated  
11 to the abdomen of the dog, and by day 41, they may be recovered from either the abdomen or  
12 the thorax. L3 and L4 migrate between muscle fibers. The last molt into juvenile adults occurs  
13 between days 50 and 70 after infection. The juvenile worm (L5) reaches the smallest pulmonary  
14 arteries as early as day 67 after the infection of the dog. The juvenile worms grow and get into  
15 the greater arteries (Nelson et al. 2018). The 2-3 cm long worms reach their final length at the  
16 6-7<sup>th</sup> months. The length and the width of the maturated female is 25-30 cm and 1-1.3 mm,  
17 respectively. The adult male is 12-20 cm long, its width is 0.7-0.9 mm. Sexual maturity occurs  
18 about day 120 post infection, patent infections (i.e., having circulating microfilariae) as early  
19 as 6 months but usually by 7 to 9 months after infection (Manfredi et al. 2007, Nelson et al.  
20 2014, 2020). The lifespan of the adult worms and the microfilariae is about 5-7 and 1-2 years,  
21 respectively.

22 The endosymbiotic *Wolbachia* bacteria e.g., *Wolbachia pipientis*, have important roles in living  
23 together with all stages of heartworms. These bacteria support the development and  
24 reproduction of *D. immitis*. The bacterial endotoxin produced by *Wolbachia* bacteria are  
25 implicated in the pathogenesis and immunological response to infection (Kozek 2005, Kramer  
26 et al. 2008, Kramer and Genchi 2014, Nelson et al. 2017).

27

## 28 *Pathogenesis of HWD*

29 The major consequences of HWD arise within the lungs (Hoch and Strickland 2008a, Bowman  
30 and Atkins 2009, Farkas and Vörös 2015, Vörös 2019). The adult worms induce reactive  
31 endothelial proliferation within the pulmonary arteries by decreasing the elasticity and diameter  
32 of their wall. Villous myointimal proliferation also occur. Later, edema formation and



1 perivascular (inflammatory) tissue reactions happen within the parenchymal parts of the lungs,  
2 and even fibrosis as well as partial lung consolidation. Vasoconstriction of the pulmonary  
3 arteries, secondary hypoxemia, endothelin-1 release as well as detrimental compounds released  
4 by the HWs contribute to the pathophysiology of HWD. As a consequence of this  
5 pathophysiology, pulmonary vascular resistance will increase, resulting in pulmonary  
6 hypertension (PHT). Spontaneously and/or during the treatment dying and fragmented HWs  
7 cause further damage of the pulmonary arteries together with thrombus formation. These  
8 fragments and thrombi can elicit embolization and occlusion of the vessels. Exercise of the  
9 patients increase pulmonary blood flow pressing the died and collapsed worms, their fragments,  
10 and the thrombi even into the smaller pulmonary arteries (Rawlings et al. 1983, Bowman and  
11 Atkins 2009, Nelson et al. 2020).

12 The damaged pulmonary arteries will be tortuous and dilated, mainly because of the increased  
13 vascular resistance and blood perfusion. Pulmonary alterations, especially PHT will cause  
14 chronic right heart pressure overload of the right heart, resulting in concentric myocardial  
15 hypertrophy with right ventricular dilation as well as increased diastolic ventricular pressure  
16 with secondary tricuspid and pulmonary valvular insufficiency. Right-sided congestive heart  
17 failure will be the sequel in severe cases (Ames and Atkins 2020, Nelson et al. 2020, Ware and  
18 Ward 2020). If there are several adult HWs within the lungs, they can wander to the main  
19 pulmonary artery and even to the right heart. The latter situation can result in the so-called caval  
20 syndrome especially in small dogs. This is the most severe clinical form of HWD due to the  
21 occlusion of the lumen of the right heart and even the entrance of the caval veins (Yoon et al.  
22 2013, Chickweto et al. 2014).

23 Besides the cardiorespiratory system, other organs can also be damaged e.g., the liver and the  
24 kidneys (Niwetpathomwat et al. 2007). In the pathophysiology of renal alterations, not only the  
25 *D. immitis*, but the symbiotic *Wolbachia* bacteria take a role as well. They contain *Wolbachia*  
26 surface protein (WSP), causing an immunoreaction and damaging the lungs as well as the  
27 kidneys (Kramer et al. 2008, Morchón et al. 2012b, Nelson et al. 2014). *D. immitis* and also *D.*  
28 *repens* can cause glomerular injury and proteinuria (Morchón et al. 2012b, Carretón et al. 2013,  
29 Falus et al. 2022). Amyloidosis, glomerulosclerosis, immune mediated glomerulopathy and  
30 chronic interstitial nephritis can also occur (Paes-de-Almeida et al. 2003, Preyß-Jägeler et al.  
31 2022). Renal thrombosis can develop, if the microfilaria burden is high and they block the renal  
32 capillaries as well (Carreton et al. 2013).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## *Clinical signs and classification*

The beginning of the disease is usually symptomless, even for 1-2 years. However, if the HWD is left untreated, the clinical consequences could be severe and even death can/will occur. The severity of HWD depends on the following factors (Nelson et al. 2014, 2018, Vörös 2019, Ware and Ward 2020):

1. The number of juvenile and adult heartworms. If more worms are in the animal, the disease is usually more severe.
2. The length of the infection. Longer infection might cause more severe symptoms.
3. Interaction between the host and the parasite. Strong immune response can cause severe clinical signs, despite the low worm burden.
4. Physical burden. Increased physical activity (e.g., in working dogs) can elicit severe symptoms due to the pathologic changes in the lungs.
5. Size of the animal. In smaller dogs, similar worm burden can cause more severe clinical signs than in larger ones.
6. The pathological effects of *Wolbachia* bacteria (see their role above).

The severity of HWD can be classified as to the results of the physical examination as well as to the radiological findings as listed in **Table 1** (Farkas and Vörös 2015, Ware and Ward 2020).

In Stage 1, the dogs do not show clinical signs, or only mild coughing occurs. By the time going, the clinical signs are worsening. In Stage 2, exercise intolerance, coughing is present, and abnormal lung sounds can be heard. In stage 3, these symptoms worsen, and signs of right-sided heart failure (ascites, hepatomegaly) also develop. The most severe Stage 4 is the so called caval syndrome. Its most frequent clinical signs are quick worsening, severe lethargy, as well as hemoglobinemia and hemoglobinuria (Di Sacco and Vezzoni 1992, Farkas and Vörös 2015, Nelson et al. 2020). The radiological alterations affect mainly the pulmonary arteries and – especially later – the interstitium of the lungs as listed in **Table 1**.

Stage		Symptoms	Radiographic changes
1.	Mild	Asymptomatic or mild coughing	None
2.	Moderate	Coughing, fatigue, abnormal breathing sounds	Moderate enlargement of the pulmonary arteries; ± perivascular and mixed alveolar/interstitial infiltration, possibly right heart enlargement
3.	Severe	Coughing, fatigue, dyspnea, abnormal cardiac and respiratory sounds (cardiac murmurs), enlarged liver (hepatomegaly), Adams-Stokes syndrome (syncope due to hypoxemia), ascites, death	Moderate or severe enlargement of pulmonary arteries, abnormal, torturous shape, and course; perivascular or diffuse, mixed alveolar/ interstitial infiltration; enlargement of the right heart; ± signs of thromboembolism: worsening of the pulmonary infiltration, mainly as an alveolar pattern, in the caudal lobes
4.	Caval syndrome	Sudden worsening (severe lethargy and weakness), hemoglobinemia, hemoglobinuria	More severe forms of the aforementioned changes, mainly the enlargement of the right heart and the pulmonary trunk (main pulmonary arteries)

1 Table 1. Stages of heartworm disease based on the clinical symptoms and radiologic findings  
2 (Farkas and Vörös 2015, Ware and Ward 2020)

### 3 Diagnosis of heartworm disease

4 The relevant parasitological methods have their distinguished role in the diagnosis of HWD  
5 (Hoch and Strickland 2008a, Bowman and Atkins 2009, Farkas and Vörös 2015, ESDA  
6 Guideline 2017).

7 For detecting the mf, the modified Knott test is used mostly (Jacsó and Fok 2006, Majoros and  
8 Juhász 2015a, Majoros and Juhász 2015b, Genchi et al. 2018). The Knott technique is rather  
9 applicable for detecting microfilaraemia without definitive distinction of *D. immitis* and *D.*  
10 *repens* regarding the everyday clinical practice (Magnis et al. 2013).


11 The most sensitive and reliable diagnostic technique for in vivo diagnosis of blood filarioids is  
12 the polymerase chain reaction (PCR) technique as a molecular biological method (Favia et al.  
13 1996, Rishniw et al. 2006, Latrofa et al. 2012, Rojas et al. 2015). This method allows definitive  
14 determination and distinction of *D. immitis* and *D. repens* if there are at least 4 mf in 1 mL  
15 peripheral blood (Gioia et al. 2010).

1 The circulating HW antigens are produced only by the adult female *D. immitis* worms (Roth et  
2 al. 1993, Goodwin 1998, Atkins 2003). Some factors e.g., the number of adult female worms,  
3 or the amount of the circulating antigens affect the sensitivity and specificity of the serological  
4 methods (Roth et al. 1993, Lee et al. 2011, Aron et al. 2012, Burton et al. 2020). Antigen (Ag)  
5 tests are especially important in cases of occult dirofilariosis (more precisely occult heartworm  
6 infection) when no mf can be detected in the peripheral blood despite a persisting HW infection  
7 with the presence of adult female worms. Occult dirofilariosis can have various etiologies e.g.,  
8 previous macrocyclic lactone application for prevention, unisex infections, or when the mf are  
9 eliminated from the peripheral blood by the immune system of the infected dog. The latter  
10 phenomenon is called true occult dirofilariosis (Wong et al. 1973, Rawlings et al. 1982, Bagi et  
11 al. 2017). The Knott test and the PCR assay is not indicated for in vivo determination of occult  
12 dirofilariosis, as there is no circulating mf. Therefore, the diagnostic accuracy of the Ag tests is  
13 of utmost importance in occult dirofilariosis, as the sole laboratory diagnostic method in these  
14 cases (Nelson et al. 2020). This is especially true in those regions, where both *D. immitis* and  
15 *D. repens* may occur either separately or simultaneously in infected dogs (Ionica et al. 2015,  
16 Ciuca et al. 2016a, b, Bagi et al. 2017, Farkas et al. 2020).

#### 17 *Further clinical diagnostic methods*


18 Diagnostic imaging techniques are applied mainly in HWD to determine the severity of the  
19 disease which strongly influences the complexity of the treatment and outcome of the disease.

20 *Respiratory radiology* can help to show the pulmonary changes caused by HWD and to  
21 diagnose or rule out other pulmonary pathologies. The radiographs should be done in (possibly  
22 right and left) lateral as well as in dorsoventral projections, for visualizing the lungs including  
23 their pulmonary vasculature. The width of the pulmonary arteries should not be larger than the  
24 width of the ninth rib or the diameter of the relevant bronchus (Ware 2014). At the early phase  
25 of the disease, mostly the smaller arteries are affected especially at the dorsocaudal edges of  
26 the lung lobes. In progressed HWD, the main pulmonary arteries as well as the larger branches  
27 are dilatated, torturous and truncated (Thrall and Calvert 1983, Losonsky et al. 1983, Atkins  
28 2010). In addition, an interstitialalveolar pattern of the lungs is also visible as shown on **Figure**  
29 **1** and **Figure 2**. In severe cases, cardiomegaly can also be diagnosed, mainly as the enlargement  
30 of the right heart (Rawlings 1986, Calvert and Rawlings 1988, Bowman and Atkins 2009,  
31 Nelson et al. 2020).



1

2 *Figure 1. Lateral radiograph of the thorax of a dog with severe (Clinical Stage 3) heartworm*  
3 *disease. The lobar arteries are dilated and tortuous, particularly in the caudal lung lobes (\*).*  
4 *Some patchy and diffuse interstitial patterns also appear in the caudal lung lobes. From Becker*  
5 *et al. 2022b. (With permission.)*




1

2 *Figure 2. Ventrrodorsal radiograph of the dog seen in Figure 1. Severe (Clinical stage 3)*  
3 *heartworm disease. The caudal lobar arteries are dilated (white arrows). The cardiac shadow*  
4 *has a reverse D shape because of the dilated right heart (black arrows). The bulging of the*  
5 *cardiac silhouette in the left craniolateral segment may indicate dilatation of the pulmonary*  
6 *trunk (\*). From Becker et al. 2022b. (With permission.)*

7

8 *Echocardiography* reveals the cardiovascular changes elicited by the elevation of the  
9 pulmonary arterial pressure e.g., dilation and hypertrophy of the right ventricle mainly in  
10 advanced cases. Right atrial dilatation and secondary tricuspid or pulmonary insufficiency can  
11 also occur. These pathologies contribute to assess the severity of HWD. Measuring the grade  
12 of tricuspid insufficiency is useful to quantify pulmonary hypertension as demonstrated on  
13 **Figure 3.** In mild cases (Clinical stages 1 and 2) echocardiography is an option being beneficial  
14 to follow up the cardiovascular changes during the therapy. In Stage 3, it is inevitable to  
15 perform, because of the high prevalence of pulmonary hypertension and right-sided heart  
16 failure, both needing appropriate therapy.




1

2 *Figure 3. Severe (Clinical stage 3) heartworm disease in a dog. The maximal speed (Vel) of the*  
 3 *tricuspid regurgitation is 358.74 cm/sec whilst the calculated pressure gradient (PG) yields*  
 4 *51.48 mmHg, representing tricuspid insufficiency caused by pulmonary hypertension (PHT).*  
 5 *Continuous Doppler echocardiographic image, left apical, four-chamber view. On the top, the*  
 6 *color Doppler part of the duplex echocardiographic image can be seen with the color signal of*  
 7 *obvious regurgitation. Left apical, caudal, four-chamber view. From Becker et al. 2022b. (With*  
 8 *permission.)*

9


10 In some cases (mainly in Clinical stage 2 and 3), adult heartworms are visible in the main  
 11 pulmonary artery (**Figure 4**).



1  
 2 *Figure 4. Cross-sections of adult heartworms (arrows) in the right pulmonary artery of a dog*  
 3 *(Clinical stage 2). Two-dimensional echocardiographic image. Right parasternal short axis*  
 4 *plane at the bifurcation of the main pulmonary artery. AO: aorta, PT: pulmonary trunk, RPA:*  
 5 *right pulmonary artery), LPA: left pulmonary artery. (Courtesy of Dr. Károly Vörös.)*

6  
 7 In severe HWD, the adult worm can also be present in the right atrium as well as in the orifice  
 8 of the tricuspid valve especially if caval syndrome develops (Stage 4). This syndrome can only  
 9 be diagnosed by echocardiography (**Figure 5**).





1  
 2 *Figure 5. Cross-sections of adult heartworms (arrows) in the right atrium of a dog with caval*  
 3 *syndrome (Clinical stage 4). Two-dimensional echocardiographic image. Right parasternal*  
 4 *long axis plane four-chamber view. RV: right ventricle, RA: right atrium, TV: tricuspid valve,*  
 5 *VS: ventricular septum, LV: left ventricle, MV: mitral valve, LA: left atrium. (Courtesy of Dr.*  
 6 *Károly Vörös.)*


7 Visualization of adult heartworms in the main pulmonary artery or in the right heart can provide  
 8 a definitive diagnosis. The body wall of the adult heartworms is highly echogenic and appears  
 9 like “equal sings” (Venco et al. 2003, Túri and Hetey 2014, Nelson et al. 2014, 2020).  
 10 However, the exact number of heartworms could not be assessed, because adults locating  
 11 deeper in the pulmonary arteries, within the lungs are not visible. Exact counting of the adult  
 12 heartworms is not possible even in the main pulmonary artery. Namely, the same parasite could  
 13 be visualized multiple times as its cross-sections, because of their location and body  
 14 conformation. It is also important to mention, that the absence of adult HWs during  
 15 echocardiography does not rule out the disease.

1 Electrocardiography (ECG) is applied less frequently as arrhythmias are rare in HWD, even in  
2 severe cases. Signs of right atrial and ventricular enlargement might be present on the ECG  
3 recordings in advanced HWD (Lombard and Ackerman 1984).

#### 4 *Treatment of HWD*

5 The American Heartworm Society (AHS) recommends the complex, three-dose alternate  
6 melarsomine protocol for the treatment of HWD. This therapeutic schema includes a  
7 macrocyclic lactone (ML) four-times monthly against microfilariae as well as L3 and L4, a 28-  
8 day long application of doxycycline against *Wolbachia*, and a 3-dose regimen of melarsomine  
9 dihydrochloride for destroying adult heartworms (Nelson et al. 2014, 2020).

10 The different stages of the life cycle have different susceptibility to the macrocyclic lactones  
11 and melarsomine used during the complex therapy. This is the so-called susceptibility gap  
12 (Figure 6). During this period, mf and L4 larvae are destroyed, while L5 larvae develop further  
13 until they become susceptible to melarsomine (Nelson et al. 2020).



15 *Figure 6. The schematic of the complex therapy of heartworm disease. Based on Nelson et al.*  
16 *2014, Farkas and Vörös 2015.*

17 For heartworm prevention, MLs i.e., selamectin, ivermectin, moxidectin, and milbemycin  
18 oxime are approved by the Food and Drug Administration (FDA) (Nelson et al. 2014, 2020).  
19 As to Nelson et al. (2020) prevention of HWD should be started as early as possible, namely,  
20 no later than 8 weeks of age. A comprehensive list of prevention protocols can be found in the  
21 ESDA Guideline (2017) addressing puppies as to their age from 2 months to more than 7  
22 months, depending on the suggestion of the manufacturers as well as history of the dogs.

23 Till the time of writing my thesis, only ivermectin has been used as part of the complex  
24 treatment protocol as recommended by the AHS. The combination of doxycycline and

1 ivermectin eliminates the L3 and L4 better, than doxycycline alone (Bazzocchi et al. 2008). The  
2 use of this combination before the three-dose melarsomine injection reduces the respiratory  
3 complications and heartworm related deaths (Nelson 2012, Nelson et al. 2017). There is a  
4 publication evaluating the outcome of the three-dose alternate therapeutic regimen including  
5 ivermectin (Maxwell et al. 2014). Topical moxidectin is approved by FDA to eliminate  
6 microfilariae for prevention of HWD. In a study on experimentally infected dogs, no adverse  
7 reaction was reported when microfilaremia was treated with moxidectin (McCall et al. 2014).  
8 Selamectin has a mild and lengthened effect against microfilariae compared to the other MLs  
9 used for HW prevention. Therefore, the chance of an adverse effect is considerably low even  
10 in microfilaremic dogs. However, selamectin is not applied as a part of the complex HWD  
11 treatment, probably because it would lengthen the duration of the therapy.

12 Melarsomine is highly effective against adult HWs, and it is the only adulticide drug approved  
13 by the FDA and recommended by the AHS given as intramuscular injection (Nelson et al. 2014,  
14 2020). Due to the potential local (e.g., irritation, swelling or pain) and systemic posttreatment  
15 side effects, this drug should be applied cautiously, with strict adherence to the instructions of  
16 the manufacturers (Boehringer Ingelheim Immiticide® 2020, Zoetis, Inc. Diroban® 2020).  
17 Melarsomine should be injected deep intramuscularly in the epaxial muscles, at the region  
18 between the third and fifth lumbar vertebrae. Pulmonary arterial thromboembolism can occur  
19 during the spontaneous death of HWs as to the defensive mechanism of the dog. However,  
20 posttreatment thromboembolism (PTE) is even expected after successful adulticide therapy.  
21 This is elicited by the dead heartworms, which collapse, maybe fragmented, and are forced by  
22 the blood flow into the small, distal pulmonary arteries. The clinical sequelae of PTE can be  
23 minimized by strict exercise restriction during and after treatment (Rawlings et al. 1983,  
24 Bowman and Atkins 2009, Nelson et al. 2020).

25 Doxycycline is an antibiotic used against the *Wolbachia* bacteria, that contributes to kill *D.*  
26 *immitis* at all life stages (Kramer et al. 2008, Kramer and Genchi 2014, Nelson et al. 2017).  
27 However, gastrointestinal side effects can occur during the application of this drug (Schulz et  
28 al. 2011, Savadelis et al. 2018). In human and canine medicine, probiotics are found to be  
29 beneficial to prevent dysbacteriosis and restore the bacterial flora when using antibiotics  
30 (Grzeskowiak et al. 2015, Zimmermann and Curtis 2019, Schmitz 2021). As I made a search  
31 on the literature, I didn't find any articles on the combination of doxycycline and probiotics  
32 regarding the therapy of HWD or other canine diseases.

33

## 1 **Aims of the study**

2 My dissertation covers three topics which goals are as follows:

- 3 1. In the first part of the thesis, we demonstrated the difficulties and determined the  
4 possibilities of serodiagnostic methods in infected dogs living in regions where  
5 concomitant infections by *D. immitis* and *D. repens* occur. The reason of this research  
6 was that we did not find information on the validation of *D. immitis* Ag tests in dogs  
7 from these regions. The VetScan Ag test was used as a model for Ag tests and the PCR  
8 assay served as a standard for the parasitological diagnosis. Sensitivity and specificity  
9 were studied of this Ag test under these conditions. As a second goal, we aimed to  
10 demonstrate if occult dirofilariosis could be the explanation for positive Ag tests despite  
11 of a negative PCR result of *D. immitis* what we experienced sometimes in our clinical  
12 praxis. In cases with occult dirofilariosis, several antigen tests of different  
13 manufacturers were applied for the diagnosis. These was based on the hypothesis that  
14 the chance for a cross-reaction among *D. immitis* and other helminths (including *D.*  
15 *repens*) is less when more than one HW Ag tests provide positive results.
- 16 2. As mentioned above, the standard therapy of HWD is recommended by the AHS which  
17 is effective and accepted internationally. This complex therapeutic protocol includes a  
18 macrocyclic lactone (ivermectin till nowadays to destroy mf as well as L3 and L4),  
19 doxycycline against the symbiotic *Wolbachia* bacteria, and the adulticide melarsomine  
20 dihydrochloride. However, side-effects and complications might occur of using these  
21 drugs. In our related research we have modified and complemented the AHS protocol  
22 with some additional medications and therapeutic measures to decrease the possible  
23 side-effects and to further improve the efficacy and outcome of the complex treatment.  
24 For these purposes, moxidectin was used instead of ivermectin as part of the complex  
25 treatment. Before our research, there has been only one preliminary report on the  
26 application of moxidectin with the contribution of one of my supervisors. These authors  
27 only partially used three-dose alternate melarsomine protocol (Bagi et al. 2017). In our  
28 study, probiotics were added to the application of doxycycline, in order to decrease the  
29 potential gastrointestinal side-effects of this antibacterial drug. The patients were  
30 sedated with butorphanol before the intramuscular application of melarsomine injection.  
31 The exact place of the needle was determined with the help of ultrasonography.
- 32 3. Occult HWD has not been published previously in Hungary. In a case report, we have  
33 described the diagnostic workup and the treatment of a severe case, for the Hungarian

1 readers. This part of my thesis also serves for demonstration of the clinical use of the  
2 scientific results of Chapter one and two.  
3

# 1. Serodiagnostic difficulties and possibilities of heartworm disease in regions where both *Dirofilaria immitis* and *Dirofilaria repens* infections occur<sup>1</sup>

## 3 Introduction

Heartworm disease (HWD) is a worldwide distributed parasitosis caused by *Dirofilaria immitis* being present in Europe, America, Australia, and Asia. Several regions of the Central and Southern European countries are enzootic (McCall et al. 2008, Morchón et al. 2012a, Simon et al. 2012). Until 2000, HWD had been diagnosed in Hungary only in dogs imported from the USA (Boros et al. 1982, Vörös et al. 2000). The first autochthonous *D. immitis* infection was detected in a Hungarian Vizsla from the eastern part of Hungary (Jacsó et al. 2009). Since then, some papers have been published about dogs and wild canids infected with *D. immitis* in the country (Farkas et al. 2014, Tolnai et al. 2014, Bacsadi et al. 2016a, Trájer et al. 2016, Farkas et al. 2020). The other *Dirofilaria* species, *Dirofilaria repens* is present in Africa, Europe, and Asia, but not in the Americas (Simon et al. 2012, Genchi and Kramer 2017). The occurrence of this parasite has been known in Hungary for many decades (Fok et al. 1998, Széll et al. 1999, Jacsó and Fok 2006, Jacsó 2014, Farkas et al. 2020) as well as in other countries of Europe (Capelli et al. 2018).

*D. immitis* can cause fatal cardiorespiratory consequences and even death without proper treatment, whilst *D. repens* infection is less pathogenic. Their differentiation is especially important during the diagnostic work-up of clinical cases in regions where both helminths occur (ESCCAP Guideline 05 2019). For detecting microfilariae (mf) of both *Dirofilaria* species, the modified Knott test is used mostly (Jacsó and Fok 2006, Majoros and Juhász 2015a, Genchi et al. 2018). However, the Knott technique is rather applicable for diagnosing microfilaraemia without definitive distinction of *D. immitis* and *D. repens* (Magnis et al. 2013).

The polymerase chain reaction (PCR) technique as a molecular biological method can be considered as the most sensitive and reliable diagnostic method for *in vivo* diagnosis of blood filarioids (Favia et al. 1996, Rishniw et al. 2006, Latrofa et al. 2012, Rojas et al. 2015). This method allows definitive determination and distinction of *D. immitis* and *D. repens* if there are at least 4 mf in 1 ml peripheral blood (Gioia et al. 2010).

---

<sup>1</sup>This chapter is based on Becker, Zs., Holló, N., Farkas, R., Gyurkovszky, M., Reizigel, J., Olaszky, K., Vári, Z. and Vörös, K. (2022): Serodiagnostic difficulties and possibilities of heartworm disease in regions where both *Dirofilaria immitis* and *Dirofilaria repens* infections occur. Acta Vet. Hung. **70**, 92-99.

1 The circulating antigens are produced only by the adult female *D. immitis* worms (Roth et al.  
2 1993, Goodwin 1998, Atkins 2003). The sensitivity and specificity of the serological methods  
3 are affected by some factors, e.g., by the number of adult female worms and by the amount of  
4 the circulating antigens (Roth et al. 1993, Lee et al. 2011, Aron et al. 2012, Burton et al. 2020).  
5 The application of the Ag tests has its distinguished importance in cases of occult dirofilariosis  
6 (more precisely occult heartworm infection) when no mf can be detected in the peripheral blood  
7 despite a persisting HW infection with the presence of adult heartworms. Occult dirofilariosis  
8 can have various causes, e.g., previous macrocyclic lactone application for prevention or unisex  
9 infections. Another important phenomenon is the so-called true occult dirofilariosis, which  
10 occurs when the mf are eliminated from the peripheral blood by the immune system of the  
11 infected dog (Wong et al. 1973, Rawlings et al. 1982, Bagi et al. 2017). For occult dirofilariosis,  
12 the PCR assay is not indicated as *D. immitis* DNA is extracted from mf in case of *in vivo*  
13 determination. Therefore, the diagnostic accuracy of the Ag tests is of utmost importance in  
14 occult dirofilariosis, as the sole laboratory diagnostic method in these cases (Nelson et al. 2010).  
15 This is especially true in those regions, including several European countries, where both *D.*  
16 *immitis* and *D. repens* may occur in infected dogs either separately or simultaneously (Ionica et  
17 al. 2015, Ciuca et al. 2016a, b, Bagi et al. 2017, Farkas et al. 2020).

18 We have found only a few publications reporting on the application of these Ag tests in those  
19 regions where both *D. immitis* and *D. repens* are present (Ionica et al. 2015, Ciuca et al. 2016a,  
20 b). Genchi et al. (2018) have reported their experiences regarding the sensitivity and specificity  
21 of the following Ag tests: Speed Diro™(BVT-Virbac); PetChek® HTWMPF (IDEXX);  
22 Witness Dirofilaria Ag Test (Zoetis); Idexx SNAP Heartworm RT test (IDEXX). However,  
23 Genchi et al. (2018) have not compared their Ag test results with molecular biological (i.e.,  
24 PCR) methods to identify circulating mf but rather performed morphological analysis by using  
25 the Knott method. Trájer et al. (2016) and Farkas et al. (2020) have described the detection of  
26 occurrence of *D. immitis* and *D. repens* alone or concomitantly in Hungary. They used PCR  
27 without comparison with the serological diagnostic methods. It is also worth to mention that no  
28 serological tests are available to detect adult *D. repens* worms (Tarello 2011, Jacsó 2014,  
29 Genchi and Kramer 2017).

30 The VetScan Ag test (Abaxis VetScan® Canine Heartworm Rapid Test Kit) is an  
31 immunochromatographic sandwich assay test for the detection of adult *D. immitis* worms (Lee  
32 et al. 2011). Its performance in terms of sensitivity and specificity has been compared with  
33 those of numerous similar Ag tests (Atkins 2003, Lee et al. 2011, Aron et al. 2012, Rojas et al.

1 2015, Henry et al. 2018). However, these reports included canine populations from the  
2 Americas where *D. repens* does not occur.

3 In literature, we did not find reports on the validation of *D. immitis* Ag tests in dogs from regions  
4 where both *Dirofilaria* species are present. Therefore, the first goal of this study was to  
5 determine the sensitivity and specificity of the VetScan Ag test – as an example for Ag tests -  
6 in dogs originating from *D. repens* affected areas i.e., dogs with known single *D. immitis* or *D.*  
7 *repens* or with mixed infections. For these purposes, the PCR assay served as the most accurate  
8 method of our study. The second goal was to demonstrate if occult dirofilariosis could be the  
9 explanation for positive Ag tests despite of a negative PCR result of *D. immitis*. By answering  
10 these questions, we intended to demonstrate the diagnostic difficulties and possibilities of HWD  
11 in regions where concomitant infections by *D. immitis* and *D. repens* as well as occult  
12 dirofilariosis are present.

13

#### 14 **Materials and methods**

15 Altogether 71 dogs were included retrospectively into the study. These dogs were randomly  
16 selected from dogs arriving for HW screening examinations or with clinical suspect of HWD.  
17 The examinations were done at the Clinic of Internal Medicine of the University of Veterinary  
18 Medicine Budapest (UVMB), Hungary, at the Budatétény Animal Hospital, Budapest,  
19 Hungary, and the Rákosliget Small Animal Ambulatory Clinic, Budapest, Hungary. Selection  
20 criteria included performed PCR assays, with positive results of *D. immitis* and/or *D. repens* as  
21 well as VetScan Ag test studies to detect adult female HWs.

22 EDTA preserved peripheral blood taken by the veterinarians of the clinics was examined freshly  
23 or preserved at 4°C for maximum two days. Blood samples were taken at different times of the  
24 day. These timings were not recorded during the study. The modified Knott test was applied at  
25 the Department of Parasitology and Zoology, UVMB to detect circulating mf (Majoros and  
26 Juhász 2015a, Majoros and Juhász 2015b).

27 DNA was isolated from 0.2 mL of blood from each sample using NucleoSpin® Tissue kit  
28 (Macherey-Nagel GmbH, Germany). Multiplex and conventional PCRs targeting fragments of  
29 12S rDNA of both *Dirofilaria* spp. and 16S rRNA of *D. immitis* were used, respectively (Liu  
30 et al. 2005, Gioia et al. 2010). The majority of the PCRs were done at the Department of  
31 Parasitology and Zoology, UVMB, whilst some of them have been performed at the Praxislab  
32 Kft and at the Vet-Med-Labor Zrt. in Budapest, Hungary, where similar PCR assays were



1 applied. PCRs were done in 68 dogs with microfilaraemia detected by the modified Knott test.  
2 Three dogs were examined by PCR despite the negative Knott test, as they had a positive  
3 VetScan Ag test result, and their history and clinical findings suggested the possibility of HW  
4 infection. This was done keeping in mind that the PCR is more sensitive than the Knott test,  
5 i.e., it can be positive in Knott negative cases (Gioia et al. 2010, Rojas et al. 2015).

6 All samples were tested for the presence of *D. immitis* antigen with the VetScan Ag test (Abaxis  
7 VetScan® Canine Heartworm Rapid Test Kit, ABAXIS Europe GmbH, Germany). In addition  
8 to a positive VetScan Ag test, serologic test kits from other manufacturers were used in six  
9 dogs, which had negative PCR results for *D. immitis*, but positive for *D. repens*, in order to  
10 define the possibility of an occult dirofilariosis. To this end, the following Ag tests were applied  
11 on the same blood samples: DiroCHEK® Canine Heartworm Antigen Test Kit (Synbiotics  
12 Corporation, San Diego, USA); Witness Dirofilaria Ag Test (Zoetis Hungary); Idexx SNAP  
13 Heartworm RT test, (IDEXX Germany). The Ag tests were done from serum samples in the  
14 laboratory of the Department of Parasitology and Zoology, UVMB or from whole blood at the  
15 Department and Clinic of Internal Medicine, UVMB as well as at the two external clinics  
16 according to the prescriptions of the manufacturers.

17 *Statistical methods.* The sensitivity and the specificity of the VetScan Ag test were estimated  
18 in comparison to PCR results. Thus, only those cases were included in the analysis where  
19 VetScan Ag test as well as PCR results were available. The examined patients were selected as  
20 described above, therefore sensitivity and specificity of the VetScan Ag test is related to this  
21 population. The sensitivity was calculated by including cases with positive *D. immitis* results.  
22 The specificity was determined by using patients with negative *D. immitis* and positive *D.*  
23 *repens* PCR results as detailed in Results. Point estimates of sensitivity and specificity  
24 (Stevenson 2008) were accompanied by 95% Blaker confidence intervals (CI) (Blaker 2000).

25

## 26 **Results**

27 The dogs were divided into three groups based on the PCR results: Group 1: 26 (36.6%) dogs  
28 were positive only for *D. immitis*. Group 2: 21 (29.6%) dogs proved to be positive for both *D.*  
29 *immitis* and *D. repens*. Group 3: 24 dogs (33.8%) were positive only for *D. repens*.

30 The sensitivity of the VetScan Ag test was  $46/47=97.7\%$  (95% CI 89.0-99.8%) based on the  
31 compiled results of Group 1 and 2 where the dogs had PCR-proven *D. immitis* infections. For

1 the specificity of the VetScan Ag test, the results from Group 3 were used, in which dogs were  
 2 *D. immitis* negative and *D. repens* positive by PCR. The specificity of the test was 19/24=66.7%  
 3 (95% CI 45.6-83.1%).

4 Examining only Group 1 (n=26), - where all animals were positive only for *D. immitis* with  
 5 PCR - the VetScan Ag test gave positive reactions in all cases except one dog. As such, the  
 6 sensitivity in this group was 25/26 = 96.2% (95% CI 81.7-99.8%). When analyzing Group 2  
 7 (n=21), where all animals were PCR positive both for *D. immitis* and *D. repens*, the sensitivity  
 8 within this group was 100% (95% CI 84.8-100%).

9 The sensitivity and the specificity of VetScan Ag test results were compared with previous  
 10 studies performed in the USA where *D. repens* does not occur (**Table 2**).

	<b>Present study</b>	<b>Atkins 2003</b>	<b>Aron et al. 2012**</b>	<b>Henry et al. 2018</b>
Sensitivity % (95% CI)	97.7 (89.0-99.9) n=47	78.0 (72.0-84.0) n = 208	92.0 n=25	98.5 (95.7-99.7) n=200
Specificity % (95% CI)	66.7 (45.6- 83.1)* n=24	97.0 (84.0-100) n = 32	100 n=24	94.0 (83.4-98.7) n=50

11  
 12 *Table 2 Comparison of the sensitivity and specificity values of the VetScan Ag test obtained in*  
 13 *our study with those published by others. CI: Blaker 95% confidence interval; n: number of*  
 14 *tested animals; \*: Applied to patients found infected with *D. repens* and negative for *D. immitis**  
 15 *by PCR. \*\*: CI was not provided.*

16 The sensitivity of the used Ag test, calculated based on the *D. immitis* PCR positive samples of  
 17 Group 1 and Group 2, was excellent (97.7% in average). These results were similar to those of  
 18 other authors as shown in **Table 2**.

19 The specificity of the Ag test, calculated based on Group 3 with only PCR positive *D. repens*  
 20 samples, was lower compared to the reports from the USA. Atkins (2003) examined blood  
 21 samples of dogs infected experimentally with known number of adult female HWs. Aron et al.

1 (2013) as well as Henry et al. (2018) verified the Ag positivity of their blood samples by  
2 necropsy. However, *Dirofilaria* PCR detections were not performed in these previous studies.

3 The samples of 6 dogs in Group 3 were positive with VetScan Ag test, despite that their PCR  
4 results were negative for *D. immitis* and positive only for *D. repens*. Of these 6 cases, 4 dogs  
5 were also seropositive when the Witness Dirofilaria Ag test was done additionally. The other 2  
6 dogs were tested also with the Witness Dirofilaria Ag test, furthermore with the Idexx Snap  
7 Heartworm RT test, as well as with the DiroCHEK® Canine Heartworm Ag test, and all gave  
8 positive results.

9

## 10 **Discussion**

11 Several publications can be found in the literature on the evaluation of various Ag tests  
12 detecting HW infections. The sensitivity of these tests varies between 77% and 100%, while  
13 the specificity yields between 90% and 100% (Atkins 2003, Aron et al. 2012, Starkey et al.  
14 2017, Genchi et al. 2018, Burton et al. 2020). As such, they are important parts of HW screening  
15 examinations and the diagnosis of HWD. However, it is known that Ag tests of *D. immitis*  
16 infections may give false positive reaction for *Spirocerca lupi* (Aroch et al. 2015),  
17 *Angiostrongylus vasorum* (Schnyder and Deplazes 2012), and *Acanthocheilonema*  
18 *dracunculoides* (Szatmári et al. 2020). False positive cross-reaction may also occur for *D.*  
19 *repens*. Genchi et al. (2018) did not find cross-reaction when they used several Ag tests in 21  
20 cases, which were microfilaremic with Knott test. However, there was no PCR examination in  
21 that study. Ciuca et al. (2016b) performed PCRs to detect *D. immitis* and *D. repens* on 108  
22 Knott positive canine blood samples as well as DiroCHEK®, Zoetis Ag test to demonstrate the  
23 presence of adult HWs. The antigen testing for *D. immitis* showed conflicting results in the  
24 examined 12 dogs with only *D. repens* mf. Two dog samples (16%) were antigen negative both  
25 before and after the preheat treatment of blood sera. Six dog samples (50%) demonstrated  
26 antigen positivity after heating, and four samples (30%) were antigen positive both before and  
27 after pretreatment. As to the hypothesis of Ciuca et al. (2016b), these results might suggest that  
28 dogs infected with *D. repens* can produce false *D. immitis* positivity, especially after preheat  
29 treatment, or may have also an occult infection with *D. immitis*.

30 *D. repens* cross-reaction with HW Ag tests has been indirectly proven by Venco et al. (2017).  
31 They reported on two experiments in the same publication: One study included live adults of  
32 *D. immitis*, *D. repens*, *Toxocara canis*, *Toxocara cati* (syn. *T. mystax*), *Dipylidium caninum*,

1 *Taenia taeniaeformis*, and *Mesocestoides* spp. larvae which were washed and incubated with  
2 saline solution. These solutions containing excretory/secretory antigens were tested with  
3 different HW Ag tests. In their second study, sera from dogs with natural infections by *An.*  
4 *vasorum* or *D. repens*, living in areas free of heartworm disease, were tested with the same Ag  
5 tests before and after preheat treatment. They found that cross-reactions with *An. vasorum* and  
6 *D. repens* might happen, and it can even potentially occur also with other helminths. *D. repens*  
7 appeared to release more antigens – responsible for cross-reaction – than the other worms  
8 examined. Preheat treatment reduced the specificity of the test by increasing cross-reactivity.

9 False negative Ag test results might also occur, mainly due to the low number of adult female  
10 heartworms, which can influence sensitivity (Atkins 2003). It is known that the negative Ag  
11 test may become positive, after heating the blood sample (Velasquez et al. 2014, Drake et al.  
12 2015, Ames et al. 2017, Bendas et al. 2017, Savadelis et al. 2017). Other authors have also  
13 found that the occurrence of false positive reactions increased with sera preheating, thereby  
14 heating seems to decrease specificity (Venco et al. 2017, Savadelis et al. 2018, Gruntmeir et al.  
15 2020). Sobotytk et al. (2021) performed *D. immitis* Ag test with DiroCHEK® Canine  
16 Heartworm Ag test on dogs experimentally infected with *D. repens*. No cross-reaction (i.e.,  
17 false positivity) was found in any dogs prior to preheat treatment, whilst the antigen test became  
18 positive after heat treatment of the samples. They concluded that the preheat treatment of the  
19 serum possesses limited clinical value and should be applied with caution. The heating of blood  
20 samples is not recommended by the American Heartworm Society (AHS) for routine heartworm  
21 screening (Nelson et al. 2014, 2020, ESDA Guideline 2017, ESDA Guideline 2017). In  
22 addition, preheating is not included in the procedure manual of any manufacturers. For these  
23 reasons, we did not perform the preheat Ag test in our cases.

24 In the present study, we used the VetScan heartworm Ag test as an example for the in-clinic  
25 antigen tests. The results of this Ag test were compared with PCR results of known *D. immitis*  
26 and/or *D. repens* infected dogs. The sensitivity of the VetScan Ag test performed on *D. immitis*  
27 positive dog samples (Group 1 and 2) was excellent, in correlation to the relevant literature  
28 (Atkins 2003, Aron et al. 2012, Henry et al. 2018). However, its specificity was lower in Group  
29 3, where dogs were infected with *D. repens* but negative for *D. immitis*, compared to the  
30 relevant data of these reports, all from the USA where *D. repens* does not occur.

31 In our study, *D. immitis* and *D. repens* infection occurred alone or as mixed infection in a similar  
32 proportion regarding the number of cases within the three groups. This observation was  
33 confirmed by PCR albeit it differs from the observations of others. Previous studies reported

1 lower rate of mixed infections than the rate of *D. immitis* or *D. repens* cases alone (Ionica et al.  
2 2015, Ciuca et al. 2016a, b, Trájer et al. 2016, Farkas et al. 2020). Ionica et al. (2015) screened  
3 390 dogs with a multiplex PCR assay. Of them, 46 (11.8%) were positive for dirofilariosis and  
4 8 (2%) for *Acanthocheilonema reconditum* infection. In their study, coinfections with *D.*  
5 *immitis* and *D. repens* were found in 11 (23.9%) positive dogs and those with *D. repens* and  
6 *Ac. reconditum* in 2 dogs (4.3%). Ciuca et al. (2016a) examined 45 stray dogs with Knott test  
7 and 23 (51.1%) patients were positive for circulating mf. Nineteen dogs were positive for *D.*  
8 *immitis* and 4 for both *D. immitis* and *D. repens* using another type of multiplex PCR system.  
9 Ciuca et al. (2016b) have performed PCR examination using the same multiplex assay on 24  
10 dogs, which were positive for circulating mf. Six out of 24 dogs have been found infected with  
11 *D. immitis*, 12 with *D. repens* and 6 animals with both *D. immitis* and *D. repens*. In one of these  
12 cases with „mixed” dirofilariosis, *Ac. reconditum* infection has also been detected. Based on  
13 the positive DiroCHEK® Canine Heartworm Ag test before and after heat treatment of the  
14 samples, the authors have hypothesized that dogs being infected with *D. repens* might had also  
15 an occult infection with *D. immitis*. Similar hypothesis has been suggested by Rojas et al. (2015)  
16 who found *D. immitis* positivity with the Vetscan Ag test in five dogs negative by both the  
17 Knott test and PCR.

18 One of the explanations of the lower specificity obtained in our study could be the possible  
19 occurrence of occult dirofilariosis (i.e., occult heartworm disease). We suspected occult  
20 infections for 6 dogs in Group 3 which were *D. immitis* negative with PCR, but positive for *D.*  
21 *immitis* antigen with several Ag tests of different manufacturers. The *in vivo* proof of occult  
22 dirofilariosis could be the demonstration of adult heartworms in the main pulmonary arteries  
23 during echocardiography. However, no adult heartworms were detected by this imaging method  
24 in these dogs. The explanation could be that these cases of our study belonged to the 1<sup>st</sup> and 2<sup>nd</sup>  
25 clinical categories of HWD, where adult worms rarely occur in those vessels (Bowman and  
26 Atkins 2009, Nelson et al. 2020). Nevertheless, our results seem to provide a stronger argument  
27 for the coinciding presence of *D. repens* infection and occult dirofilariosis compared to those  
28 of Ciuca et al. (2016b) and Rojas et al. (2015), as these authors applied only one Ag test in their  
29 studies. Ionica et al. (2015) also performed only one Ag test and found 7 Ag-positive cases with  
30 sole *D. repens* infection i.e., without *D. immitis* PCR positivity. In our opinion, the chance for  
31 a cross-reaction caused by *D. repens* is less when several Ag tests are applied, and all are  
32 positive. This phenomenon rather speaks for occult dirofilariosis as it is supposed in our cases.  
33 The same scenario might be valid to exclude potentially false positive cross-reactions with other

1 filarioid worms like *Spirocerca lupi* (Aroch et al. 2015) and *An. vasorum* (Schnyder and  
2 Deplazes 2012).

3 In those continents/countries where both helminths occur, the parasitological diagnosis of *D.*  
4 *immitis* including its differentiation from a sole *D. repens* infection is inevitable before starting  
5 any therapy. In dogs with a positive Knott test demonstrating microfilaraemia, PCR should be  
6 performed to identify these parasites with great certainty (Favia et al. 1996, Rishniw et al. 2006,  
7 Latrofa et al. 2012, Rojas et al. 2015). However, Ag tests are also important, especially in occult  
8 dirofilariosis cases (Vörös et al. 2017, Genchi et al. 2018, Nelson et al. 2020). This issue raises  
9 significant diagnostic dilemmas when a decision should be made for the treatment of HWD  
10 (Maxwell et al. 2014, Nelson et al. 2020). At the Clinic of Internal Medicine of UVMB, we use  
11 three or sometimes even four Ag tests from different manufacturers simultaneously in cases of  
12 occult dirofilariosis (Vörös et al. 2017). The complex treatment is applied only if all tests are  
13 positive and/or adult HWs are seen in the main pulmonary arteries. However, in the *D. immitis*  
14 PCR-negative cases, even multiple positive Ag tests cannot fully exclude the possibility of a  
15 false positive cross-reaction with other blood filaroids. Nevertheless, it can be assumed that the  
16 proper treatment of HWD is better than not to perform it because of the lack of an all-round  
17 diagnostics (Nelson et al. 2020). In our patients with equivocal results, we offer the moxidectin-  
18 doxycycline therapy i.e., without melarsomine as it has been recently described (Ames et al.  
19 2017, Bendas et al. 2017, Savadelis et al. 2017, Genchi et al. 2019). Bendas et al. (2017) found,  
20 that dogs treated with moxidectin, and doxycycline could become free from adult heartworms  
21 earliest 6 months after the beginning of the therapy, and all of their patients were antigen free  
22 after 18-24 months. Savadelis et al. (2017) detected no mf after 21 days posttreatment and found  
23 the efficacy of the moxidectin/doxycycline combination in the elimination of mature *D. immitis*  
24 95.9%. Ames et al. (2017) found that the combination protocol of moxidectin and doxycycline  
25 is well tolerated in most of the dogs with HWD (96%), They offered melarsomine therapy for  
26 the owners of 5 patients after 210 days of moxidectin - doxycycline treatment for HWD dogs  
27 still being antigen positive. Nevertheless, owners decided to continue the moxidectin and  
28 doxycycline treatment even in those dogs. However, from their 22 patients, 1 dog still had  
29 positive antigen test after 701 days. The AHS does not suggest protocols containing long-term  
30 macrocyclic lactone administration without melarsomine, due to the long treatment time, whilst  
31 HWD can progress, the necessity of long-term exercise restriction, and the potential of  
32 development of macrocyclic lactone resistance in HW subpopulations (Nelson et al. 2020).

1 The present study has several limitations. Unfortunately, there were no Ag-test-positive dogs  
2 with *D. repens* positive and *D. immitis* negative PCR results within the examined population,  
3 with echocardiographically detectable adult heartworms which could have been an *in vivo* proof  
4 of occult dirofilariosis. The PCR of blood samples, collected from the patients, were performed  
5 in three different laboratories for both financial and organizational reasons. Another limitation  
6 of the study is that we did not apply any methods to exclude *S. lupi* or *An. vasorum* infections.  
7 A cross-reaction with *D. repens* might be directly proven with *D. immitis* Ag tests on *D. repens*  
8 PCR positive dogs, then performing necropsy to exclude a simultaneous *D. immitis* infection.  
9 No such reports exist in the literature as far as I know. In our study, the occult dirofilariosis  
10 could not be confirmed definitely by post-mortem pathological examination, as all of these  
11 patients healed after successful treatment.

## 12 **Conclusions**

13 The sensitivity of the Ag test performed on *D. immitis* positive dog samples was excellent,  
14 compared to the previous reports on this subject. However, its specificity was lower in the  
15 examined dogs, which were infected with *D. repens* but negative for *D. immitis*, when compared  
16 to the related reports, all from the USA, where *D. repens* does not occur. In cases of positive  
17 *D. repens* and negative *D. immitis* PCR results, occult dirofilariosis could be the explanation  
18 for the positive *D. immitis* Ag tests. These observations highlight the importance of performing  
19 multiple Ag tests in those areas where both *Dirofilaria* species are present. This has special  
20 importance when a PCR cannot be performed in the lack of mf in the peripheral blood or when  
21 this technique reveals only the presence of *D. repens*. Further research would be required on a  
22 larger population to explore the occurrence rate of occult dirofilariosis, as well as the antigen  
23 cross-reaction caused by *D. repens* in cases of canine heartworm infections in these regions.

24

1 **2. Application of moxidectin and ultrasound-aided injection of melarsomine during the**  
2 **American Heartworm Society recommended treatment protocol in *Dirofilaria immitis***  
3 **infected dogs<sup>2</sup>**

4 **Introduction**

5 Heartworm disease (HWD), which is one of the most important canine vector-borne diseases  
6 in Europe, America, Australia, and Asia, is caused by the nematode *Dirofilaria immitis* (McCall  
7 et al. 2008, Morchón et al. 2012a, Simón et al. 2012, Farkas et al. 2020, Fuehrer et al. 2021). It  
8 is an emerging parasitosis of dogs in many European countries including Hungary, mainly due  
9 to climatic changes being favorable for transmitting mosquitoes as discussed in the Introduction  
10 chapter of my thesis.

11 The other filarioid helminth of this genus, *D. repens* occurs in Africa, Europe (also in Hungary),  
12 and Asia, but not in the Americas (Fok et al. 1998, Széll et al. 1999, Capelli et al. 2018). *D.*  
13 *repens* infection is more common in people than *D. immitis* resulting in mainly ocular and  
14 subcutaneous diseases (Engelsberg and Bläckberg 2022, Wylęgała et al. 2022).

15 Emerging importance of *D. immitis* in humans has also been reported (Laidoudi et al. 2021,  
16 Mendoza-Roldan et al. 2021). In people, the life cycle of *D. immitis* is not complete and the  
17 parasite usually elicits benign pulmonary nodules. These alterations are subclinical or cause  
18 only minor clinical symptoms. However, they have differential diagnostic dilemmas namely  
19 during thoracic radiography and computed tomography (Morchón et al. 2012a, Simón et al.  
20 2012, Malik et al. 2016). Human subcutaneous and ocular dirofilariosis caused by *D. immitis*  
21 have also been described (Avellis et al. 2011, Falidas et al. 2016, Parsa et al. 2020). Proper  
22 diagnosis, treatment, and prevention of HWD is inevitable for protecting canine patients and to  
23 inhibit human infections which are transmitted by infected mosquitoes (Mendoza-Roldan et al.  
24 2021).

25 The life cycle of *D. immitis* consists of different phases, which should be considered during its  
26 therapy (Hoch and Strickland 2008a, Bowman and Atkins 2009). All forms of the parasite live  
27 together with the endosymbiont *Wolbachia* bacteria (Kramer and Genchi 2014, Nelson et al.

---

<sup>2</sup>This chapter is based on Vörös, K., Becker, Zs., Kónya, R., Arany-Tóth, A. and Farkas R. (2022b): Application of moxidectin and ultrasound-aided injection of melarsomine during the American Heartworm Society recommended treatment protocol in *Dirofilaria immitis* infected dogs. *Vector Borne Zoonotic Dis.* **22**, 382-390. and Vörös, K., Becker, Zs., Dudás-Györki, Z., Gronover, B.S. and Szalay F. (2022a): Ultrasonography of the paralumbar muscles as a new aid during melarsomine treatment in canine heartworm disease. *Acta Vet. Hung.* doi:10.1556/004.2022.00034. Online ahead of print



1 2017). The details of the life cycle of the parasite are outlined in the Introduction chapter of my  
2 thesis.

3 The American Heartworm Society (AHS) recommends the three-dose alternate melarsomine  
4 protocol to treat HWD. This therapeutic regimen includes monthly application of a macrocyclic  
5 lactone (ML) through 4 months against microfilariae as well as L3 and L4, a 28-day course of  
6 doxycycline against *Wolbachia*, and a 3-dose regimen of melarsomine dihydrochloride for  
7 destroying adult heartworms (Nelson et al. 2014, 2020).

8 Among the macrocyclic lactones, selamectin, ivermectin, moxidectin, and milbemycin oxime  
9 are approved by the Food and Drug Administration (FDA) for heartworm prevention (Nelson  
10 et al. 2014, 2020). The AHS treatment protocol recommends the preventive dose to reduce new  
11 infections and eliminate susceptible larvae. Adverse (anaphylactic i.e., shock like) reactions are  
12 rare with these macrocyclic lactones at preventive doses, but caution is advised. Pretreatment  
13 with antihistamines and glucocorticoids minimize potential hypersensitivity reactions  
14 (Bowman and Atkins 2009, Nelson et al. 2014, 2020).

15 At present, ivermectin is the only ML that has been used in published studies as part of the AHS  
16 protocol. It has been shown that doxycycline/ivermectin eliminates *Wolbachia* better than  
17 doxycycline alone (Bazzocchi et al. 2008). Kramer et al. (2011) reported that dogs treated with  
18 ivermectin, doxycycline and melarsomine had a virtual absence of pulmonary thrombi. These  
19 were terminal studies that provided histopathology documenting these positive effects. To date,  
20 no one has conducted similar studies with moxidectin in place of ivermectin as to the available  
21 literature. Dogs receiving doxycycline and ivermectin prior to the three-dose melarsomine  
22 injections had fewer respiratory complications and heartworm-related death than dogs without  
23 doxycycline (Nelson 2012, Nelson et al. 2017). There is a publication evaluating the outcome  
24 of the three-dose alternate therapeutic regimen including ivermectin (Maxwell et al. 2014).  
25 Topical moxidectin is approved by (FDA) to eliminate microfilariae for prevention of HWD.  
26 In a study on experimentally infected dogs, no adverse reaction was reported when  
27 microfilaremia was treated with moxidectin (McCall et al. 2014). There is only a preliminary  
28 report on the application of moxidectin instead of ivermectin. These authors partially used  
29 three-dose alternate melarsomine protocol (Bagi et al. 2017).

30 Doxycycline is applied perorally to eliminate *Wolbachia* bacteria which contributes to the death  
31 of *D. immitis* at all life stages (Kramer et al. 2008, Kramer and Genchi 2014, Nelson et al.  
32 2017). However, side effects might occur, the most common ones being gastrointestinal

1 disorders (anorexia, vomiting, diarrhea, and weight loss) (Schulz et al. 2011, Savadelis et al.  
2 2018). During several oral antibiotic treatments, probiotics are added to prevent dysbacteriosis  
3 by restoring the bacterial flora and to help with antibacterial treatment in human and canine  
4 medicine as well (Grzeskowiak et al. 2015, Zimmermann and Curtis 2019, Schmitz 2021).  
5 When searching through the literature, I did not find publications on the combination of  
6 doxycycline and probiotics regarding the therapy of HWD or other canine diseases.

7 Melarsomine is highly effective against adult HWs, and it is the only adulticide drug approved  
8 by the FDA and recommended by the AHS given as intramuscular injection (Nelson et al. 2014,  
9 2020). This drug, however, might have systemic and local posttreatment side effects and it  
10 should be applied with strict adherence to the directions of the manufacturers (Boehringer  
11 Ingelheim Immiticide® 2020, Zoetis Inc., Diroban®, 2020). Posttreatment thromboembolism  
12 (PTE) is expected after successful adulticide therapy. This is elicited by the dead heartworms,  
13 which collapse, maybe fragmented, and are forced by the blood flow into the small, distal  
14 pulmonary arteries. The clinical sequelae of PTE can be minimized by strict exercise restriction  
15 during and after treatment (Rawlings et al. 1983, Bowman and Atkins 2009, Nelson et al. 2020).  
16 According to the manufacturer's prescriptions, melarsomine should be injected only by deep  
17 intramuscular injection in the epaxial (lumbar) muscles in the 3<sup>rd</sup> through 5<sup>th</sup> lumbar region.  
18 Local side effects like irritation, swelling and pain at the injection site are common but usually  
19 mild. Persistent nodule formation can also occur, mostly without clinical consequences (Atkins  
20 and Miller 2003, Maxwell et al. 2014, Boehringer Ingelheim Immiticide® 2020, Zoetis Inc.,  
21 Diroban® 2020). Rarely, severe swelling, sterile abscess or even progressive myelopathy can  
22 also develop. The later complication is possibly caused by improper restraint and application  
23 followed by ongoing sterile inflammation along the fascial planes or nerve roots into the  
24 epidural space (Hettlich et al. 2003, Moore et al. 2013). To minimize or even avoid local  
25 complications, it would be useful to further determine the exact location and depth of the  
26 injection needle, which is optimally the middle of the paralumbar musculature. Our research  
27 group published a report on an ultrasound method for imaging the intramuscular application of  
28 melarsomine (Vörös et al. 2022a). This technique proved to be useful before and after  
29 melarsomine injections to determine the injection site and to follow potential posttreatment  
30 local side effects.

31 The main goal of the present research was to complement the 2014 AHS therapeutic protocol  
32 with some additional therapeutical measures and supplementary medications, in order to  
33 improve the efficacy of the treatment with special regard by applying moxidectin instead of

1 ivermectin and to minimize the potential post-therapeutic complications of doxycycline and  
2 melarsomine.

3

#### 4 **Materials and methods**

5 This prospective study involved 44 dogs treated at the Small Animal Clinic of the University  
6 of Veterinary Medicine, Budapest (SAC of UVMB) between July 2014 and March 2020.  
7 Written and signed owner's consent was obtained in each case. The implemented procedures  
8 were compliant with the guidance of the Animal Welfare Committee of the UVMB.

9 The modified Knott-test was applied to detect circulating microfilariae (Genchi et al. 2007).  
10 Circulating antigens of *D. immitis* were determined by the VetScan antigen test (Abaxis  
11 VetScan® Canine Heartworm Rapid Test Kit, ABAXIS Europe GmbH, Griesheim, Germany)  
12 as described earlier (Becker et al. 2022a). Multiplex and conventional PCR techniques were  
13 used in cases of microfilaremia to identify *D. immitis* and/or *D. repens* infections as published  
14 (Gioia et al. 2010, Farkas et al. 2020). In dogs without microfilaremia i.e., in occult dirofilariosis  
15 (Wong et al. 1973, Rawlings et al. 1982), PCR was not done. Therefore, the diagnosis of HW  
16 infection of these cases was based on the simultaneous positivity of at least two and maximum  
17 four antigen tests of different manufacturers as reported previously (Vörös et al. 2017, Becker  
18 et al. 2022a) and discussed in Chapter 1 and 3 of my thesis.

19 Data were collected about the history, signalment, and a detailed physical examination was  
20 done, especially on the cardiorespiratory system. Thoracic radiography and echocardiography  
21 were also applied. After that, the dogs were classified into the four pretreatment clinical stages  
22 as described in the Introduction chapter of this thesis. M-mode, two-dimensional, and Doppler  
23 echocardiography also served for determination of cardiological consequences of HWD and to  
24 detect adult HWs within the main pulmonary artery and in the right heart (Lombard and  
25 Ackerman 1984, Venco et al. 2003, Brown and Gaillot 2008).

#### 26 *Treatment*

27 The modified and expanded therapeutic regimen applied in this study is summarized in **Table**  
28 **3**, as compared to the original three-dose alternate melarsomine management protocol (Nelson  
29 et al. 2014). Dosages of the applied drugs are also indicated in **Table 3**. Patients of Clinical  
30 Stage 3 were stabilized first by symptomatic treatment, to treat right heart failure (Hoch and

- 1 Strickland 2008b, Ware 2014). In these cases, the therapy of HWD was started 10-14 days later,
- 2 depending on the clinical status of the patient.

<b>Day</b>	<b>AHS recommended management protocol*</b>	<b>Modifications and additional therapy of the present study**</b>
Day 0	Begin exercise restriction. If the dog is symptomatic: stabilize with appropriate therapy and nursing care. Prednisone prescribed orally from day 1, at 0.5 mg/kg BID 1 <sup>st</sup> week, 0.5 mg/kg SID 2 <sup>nd</sup> week, 0.5 mg/kg EOD 3 <sup>rd</sup> and 4 <sup>th</sup> weeks.	<i>To prevent anaphylaxis</i> if mf detected: prednisolone prescribed orally from one week before day 1, applying the same therapeutic regimen for 4 weeks. <i>To prevent thromboembolism</i> possibly caused by mf: clopidogrel 2-4mg/kg/SID orally. To prevent GI side effects of prednisolone: famotidine 0.5-2.0 mg/kg SID (BID) po. or omeprazole 0.5-1.0 mg/kg SID (BID) po.
Day 1	Administer heartworm preventive*** If mf detected, pretreat with antihistamine and glucocorticoid if not already on prednisone. Observe for at least 8 hours for signs of anaphylaxis.	Heartworm preventive: moxidectin topically, applied as per package insert. <i>To prevent anaphylaxis</i> if mf detected: dexamethasone 0.1-0.2 mg/kg im. just before moxidectin application; chloropyramine 0.5-1.0 mg/kg im. 4 hours after moxidectin application.
Days 1-28	Administer doxycycline 10 mg/kg BID for 4 weeks.	<i>To prevent GI side effects of prednisolone and doxycycline</i> during day 1 to day 28: famotidine or omeprazole as written above. <i>To prevent GI side effects of doxycycline</i> : probiotics made for veterinary use during day 1 to day 28 as per package insert.
Day 30	Administer heartworm preventive.	Heartworm preventive: moxidectin topically.
Day 60	Administer heartworm preventive. First melarsomine injection 2.5 mg/kg im. Prednisone for 4 weeks as above.	Days 60, 90, and 91: Heartworm preventive: moxidectin topically.
Day 90	Administer heartworm preventive. Second melarsomine injection 2.5 mg/kg im.	<i>Before melarsomine injection</i> : Sedation with butorphanol 0.2-0.4 mg/kg im.; <i>Ultrasound examination</i> of the epaxial (lumbar) muscles to determine the exact location of melarsomine injection.
Day 91	Third melarsomine injection 2.5 mg/kg im. Prednisone for 4 weeks as above.	<i>Keeping the injection needle in place</i> for 5 minutes during injection to prevent leakage of melarsomine. <i>To prevent thromboembolism</i> : dexamethasone 0.1 (0.2) mg/kg im. before melarsomine inj.

		During the 60 <sup>th</sup> to 69 <sup>th</sup> days: dalteparin sodium 100-150 IU/kg/SID sc. for 10 days.
Day 120	Test for presence of mf. If positive treat with a microfilaricide and retest in 4 weeks.	No modifications or additional measures.
Day 271	Antigen test 6 months after completion; screen for microfilariae.	No modifications or additional measures.

1


2 *Table 3. Comparison of the three-dose alternate melarsomine AHS management protocol with*  
3 *the therapeutic scheme of the present study. \*: Nelson et al. 2014; \*\*Dosages of prednisolone,*  
4 *doxycycline, and melarsomine were the same as indicated in the AHS protocol; \*\*\*: Only*  
5 *ivermectin as part of the AHS treatment was published earlier; mf: microfilariae; im.:*  
6 *intramuscularly; GI: gastrointestinal; po.: per oral; sc.: subcutaneously.*

7

8 Microfilaremic dogs were observed for 8 to 12 hours at the SAC of UVMB intensive care unit  
9 during the day of the 1<sup>st</sup> moxidectin application, with continuous supervision. No pretreatment  
10 therapy and hospitalization were provided for dogs without microfilaremia. Exercise restriction  
11 was advised during and after the treatment period as recommended (Nelson et al. 2014).

12 Hospitalization with cage rest was done for 24 and 48 hours on the 60<sup>th</sup> and 90-91<sup>st</sup> days during  
13 melarsomine treatment. After 12 hours starvation and 4-6 hours water deprivation, butorphanol  
14 was given intramuscularly for analgesia and sedation, 25 to 30 minutes before the melarsomine  
15 injection. The patients were kept in a quiet, dark room to provide calm surroundings during this  
16 period. Then, they were placed on the examination table in sternal recumbency and were gently  
17 but properly immobilized by two persons. The melarsomine injection was given in the epaxial  
18 (lumbar) musculature (in the 3<sup>rd</sup> through 5<sup>th</sup> lumbar region) in accordance with the  
19 manufacturer's prescriptions using the alternate left and right lumbar regions during the 60<sup>th</sup>,  
20 90<sup>th</sup>, and 91<sup>st</sup> days (Merial Limited 2010).

21 The thickness of the paralumbar musculature and the exact place of the needle injection was  
22 determined by ultrasonography as described by Vörös et al. (2022a) and shown on **Figure 7**.



1

2 *Figure 7. Physiologic, oblique-horizontal sonographic image, more or less perpendicular to*  
3 *the paralumbar muscles in dog with HWD before melarsomine injection. The echogenic lines*  
4 *represent the intramuscular connective tissue spaces of the musculature (thoracolumbar*  
5 *fascia). One of them is marked with an arrow. The + signs represent the measurement points.*

6 After the injection of melarsomine, the needle was kept in place for 5 minutes to ensure  
7 absorption of the drug and to prevent its leaking into the tissues whilst pulling out the needle.  
8 Meanwhile, the patient was still immobilized by the assisting staff. Immediately thereafter, the  
9 site of injection was controlled by ultrasound examination (Vörös et al. 2022a). Water and food  
10 were supplied for the dogs only 2 and 4 hours after the injection procedure, respectively,  
11 because of the sedative effect of butorphanol, to avoid dysphagia. During each hospitalization  
12 event, the clinical status of the patients was monitored by physical examination.

13 Posttreatment systemic complications of melarsomine were checked by physical examination  
14 on the 61<sup>st</sup>, 90<sup>th</sup>, 91<sup>st</sup>, and on the 92<sup>nd</sup> days. In addition, owners and referring veterinarians were  
15 asked to provide information on the complications and the activities of the dogs by phone calls.  
16 Thoracic radiography was also performed in cases with respiratory symptoms. Local  
17 complications at the injection site were reported by the owners when they recognized painful  
18 behavior and/or swellings. In addition, physical examination of the affected epaxial lumbar  
19 musculature and ultrasonography were performed at each injection sites on the 61<sup>st</sup>, 90<sup>th</sup>, 91<sup>st</sup>,  
20 and on the 92<sup>nd</sup> days. The outcome of the treatment was checked by oral interviews either on

1 the 271<sup>st</sup> day when owners arrived at our clinic for the control Ag test, or by phone calls and/or  
2 by email correspondence when this Ag test was performed elsewhere. This timing was chosen  
3 as to the AHS recommendation issued at the time of starting this research (Nelson et al. 2014).  
4 However, Maxwell et al. (2014) found 6/18 patients being still antigen positive at this time. The  
5 explanation of this phenomenon is that dead HWs can still release antigen into the blood stream  
6 following worm death (Maxwell et al. 2014). In the latest AHS recommendation, control  
7 antigen testing is suggested even at the 365<sup>th</sup> posttreatment day (Nelson et al. 2020).

## 8 **Results**

### 9 *Data of the dogs and their parasitological results*

10 There were 24 female and 20 male patients in the population. Their age was  $5.2 \pm 3.1$  years  
11 (range 1-13 years), and their mean body weight was  $22.8 \pm 13.6$  kg (range 5-76 kg). Of the 44  
12 patients, 19 (43%), 18 (41%) and 7 (16%) dogs were categorized in Stage 1 (mild), Stage 2  
13 (moderate) and Stage 3 (severe), respectively. There were no dogs with caval syndrome,  
14 belonging into Stage 4.

15 Twenty-three out of 43 (57.5%) dogs had microfilaremia. The VetScan Ag test became positive  
16 in 43 (97.7%) cases. No microfilariae were detected in 21 dogs. PCR examinations were  
17 performed in 28 dogs, and 22 (78%) were positive for *D. immitis*, of which 8 patients were  
18 infected with both *D. immitis* and *D. repens*.


19

### 20 *Therapeutic results*

21 *Pretreatment of Stage 3 cases.* Additional symptomatic therapy was applied in 7 cases  
22 belonging to Stage 3 with favorable results, making possible to begin the complex heartworm  
23 treatment within 10-14 days. In a patient with right heart failure from Stage 3, the HWs  
24 disappeared from the right atrium and from the tricuspid valve region 10 days after cardiac  
25 treatment with furosemide, pimobendane, and potassium supplementation (**Figure 8 and 9**). In  
26 2/7 of these dogs, the adult heartworms were not seen anymore within the main pulmonary  
27 artery, 6 and 10 days after the 1<sup>st</sup> application of moxidectin, respectively.

28

29




1

2 *Figure 8. Severe (Stage 3) heartworm disease in a dog with right-side heart failure and with a*  
3 *grade 2/6 systolic, tricuspid cardiac murmur. On the pretreatment two-dimensional*  
4 *echocardiographic image, both the right atrium (JP) and the right ventricle (JK) are dilatated.*  
5 *There are several cross-sections of adult heartworms within the right atrium, at the tricuspid*  
6 *valve (TB), and even within the right ventricle, close to the tricuspid valve (arrows). One adult*  
7 *heartworm can also be seen within the dilated right main pulmonary artery (JPA) marked with*  
8 *an arrow. Right parasternal, long-axis image, four-chamber view. KS: interventricular septum;*  
9 *BP: left atrium; BK: left ventricle; MB: mitral valve. From Becker et al. 2022b. (With*  
10 *permission.)*

11





1

2 *Figure 9. Two-dimensional echocardiographic image of the dog with severe (Stage 3)*  
 3 *heartworm disease, shown on Figure 8, at the 10th day of the treatment of right-heart failure.*  
 4 *The right atrium and the right ventricle are still dilated but no heartworms can be seen. Right*  
 5 *parasternal, long-axis image, four-chamber view. TB: tricuspid valve; KS: interventricular*  
 6 *septum; BK: left ventricle; BP: left atrium; MB: mitral valve. From Becker et al. 2022b. (With*  
 7 *permission.)*

8

### 9 *Treatment of heartworm disease*

10 No anaphylactic reactions occurred during any moxidectin applications, including the 23 dogs  
 11 with microfilaremia. Adverse (side) effects of doxycycline were observed in 3 (6.8%) dogs. All  
 12 these patients were anorectic, one dog vomited, and 2 patients had diarrhea. These symptoms  
 13 healed after symptomatic therapy and by decreasing the dosage of the drug from 10 mg/kg BID  
 14 to 5 mg/kg BID. The doxycycline therapy was not ceased in either case.

15 The butorphanol premedication of the patients provided proper sedation in 42 (95.4%) cases,  
 16 while the dogs remained conscious during the whole procedure. They remained in place with  
 17 minimal restriction but could walk after the melarsomine injection procedure. The mild sedation  
 18 lasted for 1.5-2 hours. The other 2 dogs (4.6%) needed general anesthesia, with intravenous  
 19 propofol, because of excitement and aggressivity, respectively.

20 The ultrasonographic examination and cross-sectional measurements of the paralumbar  
 21 musculature allowed to plan the exact depth and site of the melarsomine injection. It was  
 22 injected into middle of the epaxial muscles, that we confirmed by ultrasound after the

1 application. By keeping the injection needle in place for 5 minutes resulted that there was no  
 2 detectable leakage of the melarsomine solution to the surface of the skin after the removal of  
 3 the needle. We observed the distribution and absorption of melarsomine macroscopically, and  
 4 it was dissolved from the injection site in 3 minutes as described (Gronover 2019, Vörös et al.  
 5 2022a).

6 Among the systemic posttreatment complications caused by melarsomine, vomitus was  
 7 observed in one (2.3%) patient, temporary diarrhea occurred in 2 (4.6%) dogs, while  
 8 pancreatitis was diagnosed in one (2.3%) case during the 1<sup>st</sup> and 2<sup>nd</sup> posttreatment days. These  
 9 symptoms were cured by symptomatic treatment within a few days. Transient anorexia occurred  
 10 in 2 (4.6%) cases, and transient polydipsia were reported by the owner in 1 (2.3%) dog. Both  
 11 symptoms ceased spontaneously within some days. Coughing and mild dyspnea was observed  
 12 in one dog (2,3%) which healed for symptomatic therapy in a few days. The comparison of our  
 13 findings and two other studies are demonstrated in **Table 4**.

<b>Side effect</b>	<b>Present study</b>	<b>Bagi et al. 2017</b>	<b>Maxwell et al. 2014</b>
Diarrhea	4,6%	21%	ND
Vomitus	2,3%	12%	ND
Anorexia	4,6%	15%	ND
Pancreatitis	2,3	ND	ND
GI side effects*	9,2*%	ND	24%
Coughing	2,3%	21%	48%
Polydipsia	2,3	ND	ND
Dyspnea	2,3%	9%	14%
Death	0%	13%	14%

14

15 *Table 4. Comparison of the side effects found in the present study with two previous studies.*  
 16 *Percentages are related to the whole numbers of patients. US: ultrasonography, GI:*  
 17 *gastrointestinal. \*: Sum of lines to 5. 2 ND: no data.*

18

19 Local reactions caused by the melarsomine injection were not found by physical examination  
 20 in 13/44 (30%) dogs. In some patients, the injection site was found within the musculature only  
 21 by the posttreatment ultrasound examinations. There were mild side effects in 29/44 (66%)  
 22 cases. Within this latter group, the owners reported only mild pain for a few days in 8 dogs. A  
 23 plum-sized, not painful swelling was found in 21 patients. These swellings did not interfere  
 24 with the daily routine lifestyle of the patients, and they disappeared within 4-6 weeks in 2 dogs,  
 25 without any therapeutic interventions. Just a small, firm nodule remained in 19 dogs. A severe,  
 26 painful, apple sized swelling occurred in 2/44 (4%) cases after the first melarsomine

1 application. In these patients, it was not possible to use alternate lumbar sites for the consecutive  
2 two injections. Rather, two melarsomine injections were applied on the same side from 2-3  
3 cm apart during the 90<sup>th</sup> and 91<sup>st</sup> days.

#### 4 *Outcome*

5 All 44 dogs healed clinically based on the physical examinations on the 120<sup>th</sup> day and on the  
6 reports of the owners. No microfilariae were detected in 33/44 patients with the Knott test on  
7 the 120<sup>th</sup> day. An Ag test was done in 33/44 dogs on the 271<sup>st</sup> day and all become negative.

8

#### 9 **Discussion**

10 The main goals of our study were to apply the three-dose alternate melarsomine therapeutic  
11 protocol (Nelson et al. 2014) with some complementation to improve the efficacy of the  
12 treatment and to decrease post-therapeutic complications, especially during doxycycline and  
13 melarsomine therapy. Although the AHS updated its recommendations in 2018 and in 2020  
14 (Nelson et al. 2018, 2020), the earlier protocol was used, as this research was started in 2014.

15 In the present study, moxidectin was applied as part of the three-dose alternate melarsomine  
16 therapy. This macrocyclic lactone is safe and efficient as a preventive drug against microfilariae  
17 (Genchi et al. 2019). McCall et al. (2014) studied moxidectin spot-on in microfilaremic dogs  
18 experimentally infected with *D. immitis*, and they did not observe any anaphylactic (adverse)  
19 reactions. Bagi et al. (2017) applied moxidectin in 22 microfilaremic dogs without any  
20 anaphylactic reactions. No anaphylaxis occurred even in our microfilaremic dogs during the  
21 present study. However, we know anecdotally from veterinarians and owners that moxidectin  
22 might elicit adverse reactions occasionally. Fok et al. (2010) reported weakness, anorexia, and  
23 nausea in 2 dogs of their 44 dogs infected with *D. repens* and treated with moxidectin. As  
24 moxidectin-elicited anaphylaxis might occur sometimes, we suggest pretreating microfilaremic  
25 patients with prednisolone and clopidogrel for one week. In addition, we give glucocorticoids  
26 and an antihistamine on the 1<sup>st</sup> day of moxidectin application together with temporary  
27 hospitalization as described earlier for ivermectin (Bowman and Atkins 2009, Yoon et al. 2013,  
28 Ware 2014, Nelson et al. 2020). Microfilariae of *D. immitis* are present in different organs  
29 histologically and can cause vascular lesions and other alterations like pulmonary  
30 granulomatous lesions (Rawlings et al. 1982, Calvert and Losonsky 1985, Calvert and Rawlings  
31 1985, Ceribasi and Simsek 2012). This is also an argument why we have pretreated our

1 microfilaremic patients with clopidogrel as a platelet aggregation inhibitor and with  
2 prednisolone during the first application of moxidectin, similarly to Yoon et al. (2013). Whether  
3 clopidogrel is useful in the post-melarsomine therapeutic period, needs further investigations  
4 (Ames and Atkins 2020). Yoon et al. (2013) applied the anticoagulant enoxaparin, which  
5 belongs to the class of low-molecular-weight heparins (LMWH). They applied this drug before  
6 the surgical retrieval of adult heartworms from the main pulmonary artery via catheterization  
7 to prevent thromboembolism. We administered a different LMWH i.e., dalteparin sodium for  
8 similar purposes after the first melarsomine injection. It remains a question whether the  
9 favorably low number of mild and temporary respiratory side effects in our cases are due to the  
10 combined post-melarsomine therapy with prednisolone and dalteparin.

11 An interesting finding which has not been reported previously is that the adult heartworms  
12 disappeared from the main pulmonary artery in 2 dogs 6 to 10 days after the first moxidectin  
13 application. In another dog of Stage 3, the adult HWs also disappeared from the right atrium,  
14 10 days after cardiac treatment of right heart failure, and they possibly moved to the pulmonary  
15 arteries. Similar observations were reported by others (Tjostheim et al. 2019, Pariaut et al.  
16 2020).

17 In addition to its effect against microfilariae and susceptible larvae, moxidectin together with  
18 doxycycline has – at least partial – adulticide effect when applying these two drugs without  
19 melarsomine. The discussion of this “slow-kill” protocol is beyond the scope of my thesis and  
20 the interested reader can refer to a recent review article of Jacobson and DiGangi (2021). In the  
21 cases of the present study, the adulticide effect of moxidectin might have been added to that of  
22 melarsomine, which can also be an explanation for the favorable (100%) recovery rate of our  
23 patients.

24 Doxycycline is used as part of the complex HWD treatment. The recommended dose (10 mg/kg  
25 BID) by the AHS is relatively high (Nelson et al. 2014, 2020) and gastrointestinal side effects  
26 can occur. Schulz et al. (2011) examined the side effects of doxycycline in 386 dogs, during the  
27 therapy of various infectious diseases. In these patients, coughing occurred in 18.3%, diarrhea  
28 in 7%, and anorexia in 2.5% of their dogs. These authors also examined blood biochemistry  
29 parameters, observing an increase of ALT activity in 39.4% and increase of ALP activity in  
30 36.4% of their cases. We also observed elevation in the liver enzymes in a few cases, however,  
31 we did not perform routine laboratory examination during the follow-up of all patients. In our  
32 study, we did not observe coughing as a side effect of doxycycline. The occurrence rate of  
33 gastrointestinal side effects in our patients (6.8%) was lower than in the report of Maxwell et

1 al. (2014). Doxycycline monohydrate has been reported to have less severe gastrointestinal  
2 complications than doxycycline hyclate (Greene and Calpin 2012). We applied the latter drug  
3 in the present study, whilst Maxwell et al. (2014) did not indicate which type of doxycycline  
4 they used. Our favorable results might also be due to the supplementation of probiotics during  
5 doxycycline application. There are experimental and human clinical studies on doxycycline  
6 therapy complemented by probiotics with a good outcome (Shah et al. 2013, Garrido-Messa et  
7 al. 2015). I did not find similar information in canine medicine. In 3/44 of our patients, it was  
8 necessary to decrease the 10 mg/kg BID dose of doxycycline to 5 mg/kg BID, similarly to the  
9 report of Maxwell et al. (2014). Additional medications (gastric protectants, antiemetics) were  
10 also applied to treat the gastrointestinal side effects in these dogs. Savadelis et al. (2018)  
11 reported that none of the dogs that received doxycycline 10 mg/kg for 28 days BID had  
12 *Wolbachia* DNA, but it was present in 25% of those who received 5 mg/kg BID. However, they  
13 recommended to apply the 10 mg/kg BID dosage for canine heartworm treatment and reduce it  
14 to 5 mg/kg BID in cases of severe gastrointestinal side effects. Carreton et al. (2020) studied  
15 recombinant *Wolbachia* surface protein (rWSP) in HW infected dogs, using three different  
16 doses of doxycycline during the AHS treatment protocol. Significant decreases of anti-rWSP  
17 antibodies were found after the administration of the three different doses of doxycycline  
18 evaluated. Based on these results, they raised the possibility that a lower dose than currently  
19 recommended would be sufficient to significantly decrease the *Wolbachia* population. During  
20 doxycycline therapy, follow-up monitoring of liver enzyme activities can be suggested,  
21 especially in older dogs and in patients with previous history of even subclinical hepatic  
22 disorders based on the study of Schulz et al. (2011).

23 Nelson et al. (2017) published a respiratory complication rate of 6.5% and 0% heartworm-  
24 related death utilizing the AHS protocol, including doxycycline, ivermectin, and the three-dose  
25 melarsomine therapy. These data are more favorable compared to those of the clinical field  
26 trials during the melarsomine approval process - without doxycycline and melarsomine - i.e.,  
27 22% and 7.0%, respectively (Keister et al. 1995). Maxwell et al. (2014) reported on the side  
28 effects of the three-dose alternate melarsomine therapy including ivermectin and regarding  
29 post-therapeutic complications and outcome. Altogether 7 (14%) of their dogs died, because of  
30 thromboembolism and progressive heart failure. One of those patients belonged to Stage 2, and  
31 two of them to Stage 3, whilst four dogs had caval syndrome, and were therefore categorized  
32 as Stage 4

1 In the present study, the number of dogs with local side effects were higher than that of Maxwell  
2 et al. (2014). However, the great majority of our patients showed only mild and temporary local  
3 reactions without clinical relevance. We applied post-therapeutic follow-up ultrasonography of  
4 the paralumbar muscles, which diagnostic procedure may also have increased the number of  
5 the detected cases with mild local alterations. In the two cases with severe, painful, apple-sized  
6 swelling we suspected individual local sensitivity to melarsomine as the injection procedure  
7 was the same as in the other dogs. Abscess formation did not occur in our patients, contrary to  
8 the three cases of Bagi et al. (2017). Maxwell et al. (2014) did not report on this complication.  
9 Incorrectly injected melarsomine can even cause spinal cord paralysis (Hettlich et al. 2003,  
10 Moore et al. 2013) which should be avoided with proper restraint and injection technique. Our  
11 favorable results regarding only mild and mainly temporary local adverse reactions can be due  
12 to the exact ultrasonographic determination of the injection site of melarsomine (Vörös et al.  
13 2022a). Sedation with butorphanol and keeping the needle in site for 5 minutes to avoid leakage  
14 also proved to be useful. Namely, melarsomine is absorbed quickly from the musculature  
15 (Boehringer Ingelheim Immiticide® 2020, Zoetis Inc., Diroban® 2020, Vörös et al. 2022a).  
16 There are different opinions in the literature regarding the necessity of restriction and sedation  
17 of patients during melarsomine injection. This procedure is suggested even without sedation  
18 and having the dogs in standing position (AHS speaks out 2021) or to use analgesics like  
19 tramadol or hydrocodone (Ames and Atkins 2020, Nelson et al. 2020). Maxwell et al. (2014)  
20 mentioned the application of butorphanol as the part of adjunctive medication without any  
21 further details. Bagi et al. (2017) used general anesthesia achieved with a combination of  
22 intravenously applied xylazine, diazepam and ketamine. We chose butorphanol, a synthetic  
23 opioid drug which has both sedative and analgesic effects with minimal cardiovascular sequelae  
24 (Vin Veterinary Drug Handbook 2021).

25 Systemic side effects of melarsomine occurred at a very low rate in our study. Anorexia and  
26 diarrhea could have been caused by melarsomine (Boehringer Ingelheim Immiticide® 2020,  
27 Zoetis Inc., Diroban® 2020). Only mild and temporary coughing occurred sporadically in a few  
28 patients during the post-melarsomine period. This might have been due to minor  
29 thromboembolism elicited by the dying and decaying parasites or as side effects of melarsomine  
30 itself (Hoch and Strickland 2008b, Bowman and Atkins 2009).

31 Unlike in the study of Maxwell et al. (2014), none of our patients died, and all of them were  
32 treated successfully. However, it is difficult to compare the results of different studies due to  
33 the variation in the population involved in each study. For example, Maxwell et al. (2014)

1 reported cases from the lower Mississippi River Valley, one of the highest endemic areas in the  
2 USA. Although both their and our cases were treated at a university hospital, tending to attract  
3 more severely affected dogs, our patients were referred from variously infected parts of  
4 Hungary. Nelson et al. (2017) reported on a similar cohort to our dogs, and no death occurred  
5 among their patients when they applied the AHS protocol involving ivermectin.

6 In general, even our Stage 1 dogs did better after HWD treatment according to the owners'  
7 reports. This observation was prominent especially regarding the performance of working dogs.  
8 Among the 44 patients, 7 dogs belonged to Stage 3 with severe HWD, and they healed as well.  
9 These favorable results might be due to the AHS therapeutic protocol supplemented with the  
10 described, additional medications with special regard to moxidectin and to the applied,  
11 additional therapeutic measures.

12 HWD cases belonging into Clinical stages 3 and 4 can have severe sequelae of the disease  
13 which should be considered during the diagnostic work-up and therapy (Ames and Atkins 2020,  
14 Ware and Ward 2020, Becker et al. 2022b). These complications include pulmonary  
15 hypertension (PHT), right sided congestive heart failure (RCHF), and pulmonary  
16 thromboembolism (PTE) which can occur even together. The clinical symptoms and  
17 radiological changes of these disorders are less specific and can be even overlapped. Additional  
18 diagnostic procedures should be applied e.g., echocardiography for PHT and RCHF as well as  
19 D-dimer measurement, thrombocyte count determination, and computer tomographic  
20 angiography (CTA) for PTE (**Figure 10, 11, 12**) to achieve the exact diagnosis as described in  
21 more details in the review of Becker et al. (2022b). To diagnose PTE, the most versatile method  
22 is CTA which has been firstly published in Hungary by our research group (Becker et al.  
23 2022b).

24




1

2 *Figure 10. CT angiography of the chest of a dog with severe (Stage 3) heartworm disease.*  
3 *Dorsal plane oblique MIP (maximum intensity projection) reconstruction image. Caudal lobar*  
4 *pulmonary arteries (\*) are tortuous and dilated. From Becker et al. 2022b. (With permission.)*


5





1

2 *Figure 11. Severe (Stage 3) heartworm disease in a dog. CT angiography, 3D reconstruction*  
3 *of the pulmonary vasculature. The left caudal lobar artery (\*) is extremely dilated and tortuous.*  
4 *Some other dilated pulmonary arteries can also be seen. From Becker et al. 2022b. (With*  
5 *permission.)*



1

2 *Figure 12. Pulmonary thromboembolism in a dog with severe (Stage 3) heartworm disease. CT*  
 3 *angiography, sagittal (a), dorsal (b), and transverse (c) reconstructed images. Both caudal*  
 4 *lobar arteries are dilated and tortuous. A large thrombus is visible in the left caudal lobar*  
 5 *artery (arrows). From Becker et al. 2022b. (With permission.)*

6 Less common complications are eosinophilic pneumonitis, eosinophilic granulomatosis, and  
 7 pneumothorax. We did not observe these phenomena among our cases till now. As such, we do  
 8 not have personal experiences on these complications. A literature review can be found in a  
 9 recent publication of our research group (Becker et al. 2022b). As to the literature, preceding  
 10 therapy of the aforementioned complications enable the specific treatment of HWD even in  
 11 severely affected patients. Thereby, adequate satisfactory clinical and complete parasitological  
 12 recovery can be reached in the majority of these dogs. They can have a good quality of life,  
 13 although their exercise capacity might be limited to an everyday regular activity without more  
 14 intensive workload. In some cases, PHT, RCHF and PTE might need a more or less long-time  
 15 maintenance therapy.

16 The detailed clinical information on vena cava syndrome (Stage 4) is also beyond the scope of  
 17 this thesis. Comprehensive description of this type of HWD can be found in the review of Farkas

1 and Vörös (2015), as well as in standard textbooks (Ware 2014, Vörös 2019, Ware and Ward  
2 2020).

3 The present study has some limitations. The results are not supported by gross pathology and  
4 histopathologic examinations, as all patients recovered. Posttreatment observations were  
5 mainly done by the owners and/or were based on our physical examinations, on phone calls and  
6 email correspondence as described in the Materials and methods section. This type of follow-  
7 up is different from the written survey of Maxwell et al. (2014) and somewhat similar to the  
8 method of Nelson et al. (2017) who utilized phone calls to ask the questions. No regular follow-  
9 up studies of our patients were performed by radiographic and clinicopathological  
10 examinations. We applied our modified therapeutic protocol on all dogs. As such, no control  
11 group receiving only the original AHS schema was formed. The reason for this that our  
12 preliminary experiences were quite favorable. As such, we did not want to curtail our patients  
13 of the advantages provided by our modifications during the treatment of HWD.

#### 14 **Conclusions**

15 In this research, during the treatment of heartworm disease, moxidectin was used instead of  
16 ivermectin, probiotics were added to the admission of doxycycline and the patients were sedated  
17 with butorphanol before the application of melarsomine injection. The exact place of the needle  
18 was also determined, by the help of ultrasonography. With the applied therapeutic modifications  
19 and complementary measures compared to the AHS 2014 protocol, satisfactory results were  
20 achieved regarding the outcome and the mainly mild post-therapeutic systemic and local  
21 complications with respect to the previous report of Maxwell et al. (2014). The mild post-  
22 therapeutic systemic alterations were basically not different from the satisfactory data of Nelson  
23 et al. (2017). All 44 patients were symptomless one month after the 3<sup>rd</sup> melarsomine injection  
24 and healed parasitologically at the control examination on the 271<sup>st</sup> day regarding the 33/44  
25 dogs examined with Ag tests. Further research including regular follow-up by radiography and  
26 clinicopathological examinations might be useful to expand the results of this study.

27

### 1 **3. Description the diagnosis and treatment of a dog with occult heartworm disease<sup>3</sup>**

#### 2 **Introduction**

3 In the case occult dirofilariosis (more precisely occult HW infection), there are living, adult  
4 heartworms in the infected animal, however, cannot be detected in the peripheral blood (Calvert  
5 et al. 1999, Nelson et al. 2014, Thomason and Calvert 2015, Atkins 2017, Ware and Ward  
6 2020). This type of HW infection can have several reasons as described in the 1<sup>st</sup> Chapter of  
7 this thesis. Briefly: too low number in the peripheral blood to detect by the Knott test; previous  
8 macrocyclic lactone application for prevention of dirofilariosis; unisex infections with only  
9 male or female mf transmitted by the mosquito; or mf are eliminated from the peripheral blood  
10 by the immune system of the infected dog. The latter phenomenon is called true occult  
11 dirofilariosis (Wong et al. 1973, Rawlings et al. 1982). The Knott test and most commonly also  
12 the PCR assay reveals negative results, as there is no (not enough) circulating mf. During HWD,  
13 echocardiography can be of diagnostic value when adult HWs are seen in the main pulmonary  
14 artery and/or in the right heart (Lombard and Ackerman 1984, Brown and Gaillot 2008, Túri  
15 and Hetyey 2014, Bagi et al. 2017). The diagnostic method proved to be valuable also in one  
16 previous report including occult dirofilariosis cases as well (Badertscher et al. 1988).

17 The major goal of this case report is to demonstrate the main clinical features as well as the  
18 diagnostic and therapeutic procedures of a dog with true occult dirofilariosis which has not been  
19 published previously in Hungary. This case report is also an example of the diagnostic work-  
20 up and therapeutic management of severe HWD caused by occult dirofilariosis with special  
21 regard for applying multiplex Ag tests in these cases. The latter has never been published as to  
22 our search through the international literature.

#### 23 **History**

24 A 4-year-old, 38 kg, American Staffordshire terrier male dog was referred to the clinic of  
25 University of Veterinary Medicine Budapest in 2017 with an anamnesis of a half year long  
26 coughing. A few weeks before admission, the dog received amoxicillin-clavulanic acid,  
27 azithromycin and ambroxol for a week. However, its general status did not improve, and the  
28 coughing became more severe. Before presentation, the dog also received furosemide for 2  
29 weeks. The owners experienced, that the dog gradually became weaker and anorexic, lost

---

<sup>3</sup>This chapter is based on Vörös, K., Becker, Zs., Arany-Tóth, A., Gyurkovszky, M. and Farkas, R (2017): Okkult *Dirofilaria immitis* szívférgesség kutyában. Esetismertetés és irodalmi áttekintés. Magy. Állatorvosok Lapja. **139**, 675-685.

1 weight, had dyspnea, abdominal distension and fainting during the last few weeks. The patient  
2 received rabies vaccine four months and combine vaccine against infectious diseases  
3 (distemper, leptospirosis, hepatitis) one year earlier. At the time of vaccination, it was  
4 dewormed with a combine tablet of fenbendazole, pyrantel-pamoate and praziquantel. The  
5 dog was kept at Jászfényszaru, in a garden. Mosquitoes were common at the environment where  
6 the dog lived from its puppyhood never leaving this area. Neither repellents against mosquitoes  
7 nor macrocyclic lactones to prevent *Dirofilaria* infection were given before the referral to our  
8 clinic.

### 9 **Physical examination**

10 During the clinical examination, the patient was lethargic and reluctant to move. A mixed type  
11 dyspnea and abdominal distension were obvious. The developmental stage of the patient was  
12 appropriate regarding its breed, age, and sex. However, the dog was moderately emaciated.  
13 Rectal temperature was 38.6 °C, the pulse rate yielded 160/min, and the respiratory rate 40/min,  
14 respectively. During the detailed physical examination of the organs, its haircoat was dry and  
15 dull, and the elasticity of its skin was decreased. The mucosal membranes were cyanotic;  
16 however, the capillary refill time was normal (<2 sec). We did not observe nasal discharge. It  
17 was easy to provoke coughing. The cough was strong, long-lasting, repeated, dry, deep, and  
18 moderately painful. Stridor above the pharynx and the trachea was heard. Moderate, mixed type  
19 dyspnea was observed, mainly as a thoracic respiratory type. Bronchial sounds were heard  
20 diffusely above both sides of the thorax. In addition, crackles (crepitation) were evident, above  
21 the dorsocaudal part, mainly during inspiration. The percussion sound of the chest was duller  
22 and shorter than normal, especially at the dorsocaudal region. Regarding the circulatory system,  
23 the heartbeat was weaker during the observation and palpation of the chest. The heart sounds  
24 were rapid, rhythmic, and weaker during auscultation. The 1<sup>st</sup> and 2<sup>nd</sup> heart sounds could have  
25 been distinguished, whilst additional heart sounds and murmur were not heard. The pulse at the  
26 femoral artery were rapid, rhythmic, and weaker. The jugular veins were distended, and a  
27 positive (systolic) fluctuation was visible. The abdomen was distended, pear shaped, with  
28 severe undulation. During percussion of the abdomen, the sounds at the upper third were  
29 tympanic, below that the percussion sounds were dull, divided by a horizontal line which  
30 changed its position by elevating the animal. These signs were suggestive of the presence of  
31 free abdominal fluid. Deep palpation of the abdomen cannot be performed due to its distension.  
32 There were no changes during the physical examination of other organs.

1 **Diagnostic imaging and routine clinicopathological examinations**

2 Respiratory radiography was performed with a high frequency radiography machine (7X  
3 SUPER HF 650, PerkinElmer XRpad 4336 MED) in right laterolateral and dorsoventral  
4 projection. Right-heart enlargement, bulging of the main pulmonic trunk as well as dilatation  
5 of the pulmonary arteries and an interstitial-alveolar pattern of the caudal lung lobes were seen.

6 M-mode, two-dimensional, color Doppler and spectral Doppler examinations with an Esaote  
7 Mylab Gold 40 ultrasound machine revealed dilation of the right ventricle and right atrium as  
8 well as severe tricuspid and moderate pulmonary valve insufficiency was observed. Pulmonary  
9 hypertension was also stated based on the quantification of these valvular insufficiencies (vmax  
10 of regurgitation 4.5 m/sec, PG 81 mmHg and vmax 0.7 m/sec, PG 2 mmHg, respectively) based  
11 on Brown and Gaillot (2008). The diameters of the left ventricle in diastole and that of the left  
12 atrium in systole and diastole were below the normal limits suggesting low cardiac output of  
13 the left heart. The main trunk and the main left and right branch of the pulmonary artery were  
14 dilated, and a few cross sections of adult heartworms were visible. During ECG-examination,  
15 sinus rhythm, as well as signs of enlargement of the right atrium and ventricle were observed.  
16 On abdominal ultrasonography, enlarged (congested) liver, dilated hepatic veins and severe  
17 free abdominal fluid accumulation were visible.

18 Hematologic and routine serum biochemistry examinations performed at the Department of  
19 Pathophysiology and Oncology, UVMB resulted in the following clinicopathological  
20 alterations: leukocytosis, eosinophilia, moderate hyperglycemia, and mild hypomagnesemia.

21 **Parasitological laboratory examinations**

22 As to the history (the dog living in an endemic region) and the clinical signs, severe (Stage 3)  
23 HWD was suspected (among other diseases with right-heart failure, and ascites). The modified  
24 Knott test to detect mf was performed at the Department of Pathophysiology and Oncology,  
25 UVMB and it revealed a negative result. To control this finding, the Knott test was repeated at  
26 the Department of Parasitology and Zoology, UVMB from the same blood sample, and its result  
27 was also negative. Nevertheless, PCR was also performed at the Department of Parasitology  
28 and Zoology, UVMB as described in Chapter 1. Neither *D. immitis* nor *D. repens* infections  
29 were found.

30 Based on parasitological results as well as on the presence of adult HWs in the main pulmonary  
31 artery observed with echocardiography, occult dirofilariosis was diagnosed clinically. In order  
32 to demonstrate the presence of adult female worms, the following four antigen tests were used

1 with the same blood sample: Idexx SNAP Heartworm RT Test (Idexx Deutschland); VetScan  
2 VS2 HW test (Abaxis, USA); Witness Dirofilaria (Zoetis, USA); DiroCHEK Canine  
3 Heartworm Antigen Test Kit (Symbiotic Co. USA). Antigens of *D. immitis* were detected with  
4 each of these tests.

5 Diagnosis of occult dirofilariosis was established, supported by the aforementioned  
6 echocardiographic and parasitological findings. As the dog never received macrocyclic lactones  
7 before, true occult HWD was stated as discussed in Chapter one of this thesis. The patient was  
8 categorized into Clinical Stage 3 based on the physical examination and radiographic findings  
9 and confirmed by echocardiography.

## 10 **Treatment**

11 The severe congestive right-sided heart failure was treated with furosemide (1.6 mg/kg BID),  
12 potassium- and magnesium-aspartate (1.8 mg/kg SID), enalapril (0.4 mg/kg SID), and  
13 pimobendane (0.2 mg/kg BID). The clinical signs improved in a week: the patient's appetite  
14 become better, ascites decreased, coughing has ceased, and fainting occurred only once in the  
15 next few weeks.

16 The complex therapy of HWD as to the AHS recommendation (Nelson et al. 2014) was started  
17 on the 21<sup>st</sup> day after the clinical signs of congestive heart failure remarkably improved. The dog  
18 was treated with moxidectin 2.5%/imidacloprid 10% (Advocate® spot-on, Bayer Animal  
19 Health GmbH, Germany) to eliminate L3 and L4 larvae, four times monthly. In addition,  
20 doxycycline was started in a dose of 10 mg/kg BID per os, against the endosymbiont *Wolbachia*  
21 *pipientis* for 28 days. The adulticide melarsomine (Immiticide) injection was administered  
22 intramuscularly, the first injection was given at the 80<sup>th</sup> day, instead on the 60<sup>th</sup> day (suggested  
23 by Nelson et al. 2014) because of the previously discussed cardiorespiratory sequelae of the  
24 severe HWD.

25 No side effects of any applied drugs were observed during the complex therapy. The general  
26 status of the dog showed further improvement, the patient was in a good condition 6 months  
27 after the beginning of the complex therapy. The radiographic and echocardiographic alterations  
28 improved. The repeated Knott test and Ag tests revealed negative results at that time. The  
29 patient received the same medications for chronic treatment of the cardiac failure, which did  
30 not deteriorate even during mild to moderate activity. The dose of furosemide was decreased to  
31 the third of the initial dose, and the potassium- and magnesium aspartate were also decreased  
32 to every other day (EOD) application. The patient was in a good general state 11 months after

1 the first examination. The radiographic and echocardiographic alterations diminished even  
2 further.

### 3 **Discussion**

4 The diagnosis and treatment of HWD are detailed in the previous chapters of my thesis. As the  
5 Knott-test is negative in occult dirofilariasis, just as the PCR technique, this form of HWD can  
6 be diagnosed by applying more antigen tests of different manufacturers with the same blood  
7 sample to detect adult, female HWs (Becker et al. 2022a). In the present case, HW antigen tests  
8 from 4 different manufacturers were used, and all of them were positive. Another proof of HWD  
9 was, that adult HWs were seen in the main pulmonary artery similarly as reported by  
10 Badertscher et al. (1988). In the past, before the use antigen-tests, the diagnosis of occult  
11 heartworm disease was made by selective angiography, indirectly visualizing heartworms  
12 (Wong et al. 1973, Matic and Herrtage 1987). In the literature, the use of detecting antibodies  
13 against microfilariae (e.g., with immunofluorescent antibody procedure) has been described  
14 only for scientific research purposes (Wong et al. 1973, Rawlings et al. 1982, Boto et al. 1984).  
15 This might be useful for diagnosing the disease in a clinical setting. However, I have found one  
16 preliminary study where two versions of feline HW antibody test have been recently used in  
17 canine HWD after preheat treatment, the latter to disrupt antibody-antigen complexes (Lane  
18 2021). In that study, 14/100 stray adult dogs had positive results with feline HW Ag test.  
19 Nevertheless, the applied feline antibody tests are not commercially validated/approved for  
20 dogs.

21 In conclusion, occult HW infection can arise diagnostic dilemmas as the Knott test and the PCR  
22 will reveal negative results. In these cases, positivity of more Ag tests can support the diagnosis  
23 of HWD, even if no adult HWs can be seen within the main pulmonary artery during  
24 echocardiography (Becker et al. 2022a, Vörös et al. 2022b). Briefly, the chance for a cross  
25 reaction with other parasites is less, if more Ag tests provide positive results for HWD as  
26 outlined in Chapter 1 and 2 of my thesis. In questionable cases, the patient could receive  
27 macrocyclic lactone monthly, just as in prevention, supplemented with doxycycline in the first  
28 28 days (Atkins 2017). The macrocyclic lactone therapy, namely ivermectin and moxidectin is  
29 also efficient against *A. vasorum* and *S. lupi*, those can give cross-reaction with *D. immitis* (Le  
30 Sueur et al. 2010, Jacsó 2014, Borgeat et al. 2015).



1 The present chapter of my thesis is based on our article of Vörös et al. (2017) which is the first  
2 report on true occult dirofilariosis in Hungary. This case report is also an example of the  
3 diagnostic work-up and therapeutic management of severe HWD during occult dirofilariosis.

4

5

6

## 1 **New scientific results of the thesis**

2

- 3 - Where concomitant infections by *D. immitis* and *D. repens* occur, the sensitivity of the  
4 Vetscan Ag test was similar, and its specificity was lower compared to other studies  
5 carried out in the USA where only *D. immitis* occurs.
- 6 - In cases of positive *D. repens* and negative *D. immitis* PCR results, occult dirofilariosis  
7 can be responsible for the positive *D. immitis* Ag tests as well as for their lower  
8 specificity compared to other studies.
- 9 - In the lack of microfilaraemia, like in occult dirofilariosis, multiple Ag tests from the  
10 same blood samples should be performed, to increase the diagnostic accuracy of HWD.
- 11 - As part of the complex treatment, moxidectin is not only effective against microfilariae  
12 as well as L3 and L4 stages but its partial adulticid effect can contribute to the effectivity  
13 of HW therapy.
- 14 - Gastrointestinal side effects of doxycycline therapy can be decreased by probiotics  
15 supplementation as an additive to the complex treatment of HWD.
- 16 - Sedation with butorphanol and ultrasonographic determination of the location of the  
17 injection needle can increase the safety of the melarsomine injection and decrease the  
18 severity of its local side effects.
- 19 - Occult heartworm disease was firstly described in Hungary.

20

## 21 **References**

- 22 AHS Speaks Out 2021 AHS Board speaks out adulticide treatment: minimizing melarsomine  
23 complications. [https://www.heartwormsociety.org/veterinary-resources/veterinary-education/  
24 ahs-board-speaks-out/315-adulticide-treatment-minimizing-melarsomine-complications?  
25 highlight=WyJpbmply3Rpb24iXQ==](https://www.heartwormsociety.org/veterinary-resources/veterinary-education/ahs-board-speaks-out/315-adulticide-treatment-minimizing-melarsomine-complications?highlight=WyJpbmply3Rpb24iXQ==)
- 26 Ames, M. K., Van Vranken, P., Plath, Ch. and Atkins, C. (2017): Use of  
27 moxidectin/imidacloprid and doxycycline for non-arsenical heartworm adulticidal therapy.  
28 2017 ACVIM Forum Research Report Program, 20 July 2017, J. Vet. Internal Med. **31**, pp.  
29 1572-1604, Abstract No. 6.
- 30 Ames, M. K. and Atkins, C. E. (2020): Treatment of dogs with severe heartworm disease. Vet  
31 Parasitol. **283**, 109131.

- 1 Aroch, I., Rojas, A., Slon, P., Lavy, E., Segev, G. and Baneth, G. (2015): Serological cross-  
2 reactivity of three commercial in-house immunoassays for detection of *Dirofilaria immitis*  
3 antigens with *Spirocerca lupi* in dogs with benign esophageal spirocercosis. *Vet. Parasitol.* **211**,  
4 303–305.
- 5 Aron, K., Mehra, R., Tockman, C., and DeJong, K. (2012): Canine heartworm testing –  
6 Understanding low worm burden testing and a comparison of tests on the market. Vetcom  
7 Publication. Available at: [http://www.abaxis.com/pdf/888-4327 canine heartworm testing](http://www.abaxis.com/pdf/888-4327_canine_heartworm_testing_understanding_low_worm_burden_testing_rev_a.pdf)  
8 [understanding low worm burden testing rev a.pdf](http://www.abaxis.com/pdf/888-4327_canine_heartworm_testing_understanding_low_worm_burden_testing_rev_a.pdf); (accessed on 02/17/2016).
- 9 Atkins, C.E. (2003): Comparison of results of three commercial heartworm antigen test kits in  
10 dogs with low heartworm burdens. *J. Am. Vet. Med. Assoc.* **222**, 1221–1223.
- 11 Atkins, C. (2010): Heartworm disease. In: Ettinger, S. J. and Feldmann E. C. (eds.): Textbook  
12 of veterinary internal medicine. Diseases of the dog and cat, 7th ed., Elsevier Saunders, St. Luis.  
13 pp. 1353-1380.
- 14 Atkins, C. (2017): Canine and feline heartworm disease. In: Ettinger, S. J., Feldman, E. C. and  
15 Cote, E. (eds.): Textbook of veterinary internal medicine. Diseases of the dog and cat. Expert  
16 consult, 8th ed., Saunders, St. Luis. pp 1316-1344.
- 17 Atkins, C. E. and Miller, M. V. (2003): Is there a better way to administer heartworm adulticidal  
18 therapy? *Vet. Med.* **98**, 310-317.
- 19 Avellis, F. O., Kramer, L. H., Mora, P., Bartolino, A., Benedetti, P. and Rivasi, F. (2011): A  
20 case of human conjunctival dirofilariosis by *Dirofilaria immitis* in Italy. *Vector Borne Zoonotic*  
21 *Dis.* **11**, 451-452.
- 22 Bacsadi, Á., Papp, A., Szeredi, L., Tóth, G., Nemes, C., Imre, V., Tolnai, Z., Széll, Z. and Sréter,  
23 T. (2016a): Retrospective study on the distribution of *Dirofilaria immitis* in dogs in Hungary.  
24 *Vet. Parasitol.* **220**, 83-86.
- 25 Bacsadi, Á., Tolnai, Z., Papp, A., Szeredi, L., Tóth, G., Nemes, C., Imre, V., Széll, Z. and Sréter,  
26 T. (2016b): Emergence of parasites in the changing European environment: example of  
27 heartworm from Hungary. Short secondary communication. Paraziták terjedése a változó  
28 európai környezetben: a szívféreg példája hazánkból. Rövidített másodközlés. *Magy.*  
29 *Állatorvosok Lapja.* **138**, 295-299. (In Hungarian)

- 1 Badertscher, R.R., Losonsky, J.M., Paul, A.J. and Kellner, S.K. (1988): Two-dimensional  
2 echocardiography for diagnosis of dirofilariasis in nine dogs. J. AM. Vet. Med. Assoc. **193**,  
3 843-846.
- 4 Bagi, F., Vörös, K. and Túri, Á. (2017): Preliminary experiences of the diagnosis and complex  
5 treatment of canine heartworm disease: 38 cases. A kutyák szívférgessége megállapításának és  
6 komplex gyógykezelésének előzetes tapasztalatai 38 eset kapcsán. Magy. Állatorvosok Lapja.  
7 **139**, 203-213. (In Hungarian)
- 8 Bazzocchi, C., Mortarino, M., Grandi, G., Kramer, L. H., Genchi, C., Bandi, C., Genchi, M.,  
9 Sacchi, L. and McCall, J. W. (2008): Combined ivermectin and doxycycline treatment has  
10 microfilaricidal and adulticidal activity against *Dirofilaria immitis* in experimentally infected  
11 dogs. Internat. J. Parasitol. **38**, 1401-1410.
- 12 Becker, Zs., Holló, N., Farkas, R., Gyurkovszky, M., Reiczigel, J., Olaszky, K., Vári, Z., and  
13 Vörös, K. (2022a): Serodiagnostic difficulties and possibilities of heartworm disease in regions  
14 where both *Dirofilaria immitis* and *Dirofilaria repens* infections occur. Acta Vet. Hung. **70**, 92-  
15 99.
- 16 Becker, Zs., Vörös, K., Arany-Tóth, A. and Jerzsele, Á. (2022b): Clinical characteristics and  
17 treatment of severe heartworm disease in dogs. Literature review and own experiences. Okkult  
18 *Dirofilaria immitis* szívférgesség kutyában. Esetismertetés és irodalmi áttekintés. Magy.  
19 Állatorvosok Lapja. **144**, 473-492. (In Hungarian).
- 20 Bendas, A. J. R., Mendes-de-Almeida, F., Von Simson, C. and Labarthe, N. (2017): Heat  
21 pretreatment of canine samples to evaluate efficacy of imidacloprid + moxidectin and  
22 doxycycline in heartworm treatment. Parasit. Vectors. **10**, 246.
- 23 Blaker, H. (2000): Confidence curves and improved exact confidence intervals for discrete  
24 distributions. Can. J. Stat. **28**, 183-198.
- 25 Boehringer Ingelheim Immiticide® 2020: Boehringer Ingelheim Immiticide® [package insert],  
26 Boehringer Ingelheim Animal Health, St Joseph, MO, USA.  
27 [https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7b8c0f90-412b-4bd1-](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7b8c0f90-412b-4bd1-9b2b-afd8078e-8ecf&type=display)  
28 [9b2b-afd8078e-8ecf&type=display](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7b8c0f90-412b-4bd1-9b2b-afd8078e-8ecf&type=display).
- 29 Bokori, J. (1956): Oesophagus stricture and consecutive dilatation of the stomach caused by  
30 verminous nodules of *Spirocerca lupi*. *Spirocerca lupi* okozta féregcsomók miatt létrejött

- 1 nyelvcsőszűkület és következményes gyomorkitágulás kutyában. Magy. Állatorvosok Lapja.  
2 **11**, 189-190.
- 3 Borgeat, K., Sudunagunta, S., Kaye, B., Stern, J., Luis Fuentes, V. and Conolly, D. J. (2015):  
4 Retrospective evaluation of moderate-to-severe pulmonary hypertension in dogs naturally  
5 infected with *Angiostrongylus vasorum*. J. Small Anim. Pract. **56**, 196–202.
- 6 Boros, G., Janisch, M. and Sebestyén, Gy. (1982): *Dirofilaria immitis* in dogs. *Dirofilaria*  
7 *immitis* kutyában. Magy. Állatorvosok Lapja. **37**, 313–316. (In Hungarian)
- 8 Boto, W. M., Powers, K. G. and Levy, D. A. (1984): Antigens of *Dirofilaria immitis* which are  
9 immunogenic in the canine host: detection by immuno-staining of protein blots with the  
10 antibodies of occult dogs. J. Immunol. **133**, 975-980.
- 11 Bowman, D.D. and Atkins, C.E. (2009): Heartworm biology, treatment, and control. Vet. Clin.  
12 North Am. Small Anim. Pract. **39**, 1127–1158.
- 13 Brown, D. and Gaillot, H. (2008): Heart. In: Penninck, D. and d’Anjou, M. A. (eds.): Atlas of  
14 Small Animal Ultrasonography. Ames, USA: An Imprint of Blackwell Publishing pp. 151-216.
- 15 Burton, K. W., Liu, J., Drexel, J. P., Pulaski, C. Heartsill, S. and Dupuy, C. (2020): Comparative  
16 evaluation of field samples using 2 in-clinic assays for heartworm antigen detection in dogs.  
17 Vet. Parasitol. **283**, 109163.
- 18 Cabanová, V., Pantchev, N., Hurníková, Z. and Miterpáková, M. T. (2015): Recent study on  
19 canine vector-borne zoonoses in southern Slovakia. – Serologic survey. Acta Parasitol. **60**, 749-  
20 758.
- 21 Calvert, C. A. and Losonsky, J. M. (1985): Occult heartworm-disease associated allergic  
22 pneumonitis. J. Am. Vet. Med. Assoc. **186**, 1097-1098.
- 23 Calvert, C. A. and Rawlings, C. A. (1985): Pulmonary manifestations of heartworm disease.  
24 Vet. Clin. North Am. Small Anim. Pract. **15**, 991-1009.
- 25 Calvert, C. A. and Rawlings, C. A. (1988): Canine heartworm disease. In Fox, P. R. (ed.):  
26 Canine and Feline Cardiology. Churchill Livingstone, New York, USA, pp. 519-549.
- 27 Calvert, C. A., Rawlings, C. A. and McCall, J. W. (1999): Canine heartworm disease. In: Fox,  
28 P. R., Sisson, D., Moise, N. S. (eds.): Textbook of canine and feline cardiology. Principles and  
29 clinical practice, 2nd ed, Philadelphia, USA, WB Saunders Co. pp. 702-726.

1 Capelli, G., Genchi, C., Baneth, G., Bourdeau, P., Brianti, E., Cardoso, L. Danesi, P., Fuehrer,  
2 H. P., Gianelli, A., Ionică, A. M., Maia, C., Modrý, D., Montarsi, F., Krücken, J., Papadopoulos,  
3 E., Petrić, D., Pfeffer, M., Savić, S., Otranto, D., Poppert, S. and Silaghi, C. (2018): Recent  
4 advances on *Dirofilaria repens* in dogs and humans in Europe. *Parasit. Vectors.* **11**, 663.

5 Carreton, E., Morchón, R., González-Miguel, J., Simón, F., Juste, M. C. and Montoya-Alonso,  
6 J. A. (2013): Variation of D-dimer values as assessment of pulmonary thromboembolism during  
7 adulticide treatment of heartworm disease in dogs. *Vet. Parasitol.* **195**, 106-111.

8 Carreton, E., Morchón, R., Falcón-Cordón, Y., Falcón-Cordón, S., Matos, J. I. and Montoya-  
9 Alonso, J. A. (2020): Evaluation of different dosages of doxycycline during the adulticide  
10 treatment of heartworm (*Dirofilaria immitis*) in dogs. *Vet. Parasitol.* **283**, 109141.

11 Ceribasi, A. O. and Simsek, S. (2012): Histopathologic effects of *Dirofilaria immitis*  
12 microfilaria on internal organs of dog confirming by PCR technique. Case report. *Iran J.*  
13 *Parasitol.* **7**, 103-107.

14 Chandrasekharan, N. V., Karunanayake, E. H., Franzen, L., Abeyewickreme, W. and Petterson,  
15 U. (1994): *Dirofilaria repens* cloning and characterization of a repeated DNA sequence for  
16 the diagnosis of dirofilariasis in dogs, *Canis familiaris*. *Exp. Parasitol.* **78**, 279-286.

17 Chickweto, A., Bhaiyat, M. I., Lanza-Pera, M., Veytsman, S., Tiwari, K., De Allie, C. and  
18 Sharma, R. N. (2014): Retrospective study of canine heartworm disease with caval syndrome  
19 in Grenada, West Indies. *Vet. Parasitol.* **205**, 721-724.

20 Ciuca, L., Musella, V., Miron, L.D., Maurelli, M.P., Cringoli, G., Bosco, A. and Rinaldi, L.  
21 (2016a): Geographic distribution of canine heartworm (*Dirofilaria immitis*) infection in stray  
22 dogs of eastern Romania. *Geospat. Health.* **11**, 499.

23 Ciuca, L., Genchi, M., Kramer, L., Mangia, C., Mirona, L. D., Del Pretec, L., Maurelli, M. P.,  
24 Cringoli, G. and Rinaldi, L. (2016b): Preheat treatment of serum samples from stray dogs  
25 naturally exposed to *Dirofilaria immitis* and *Dirofilaria repens* in Romania. *Vet. Parasitol.* **225**,  
26 81-85.

27 Csöndes, J., Majoros, G., Lajos, Z., Psáder, R., Vajdovich, P., Manczur, F. and Máthé, Á.  
28 (2015): Angiostrongylosis-related restrictive pneumopathy assessed by arterial blood gas  
29 analysis in a dog. *Acta Vet. Hung.* **63**, 16-29.

- 1 Di Sacco, B. and Vezzoni, A. (1992): Clinical classification of heartworm disease for the  
2 purpose of adding objectivity to the assessment of therapeutic efficacy of adulticidal drugs in  
3 the field. Proceedings of the American Heartworm Society Symposium. Austin, Texas, USA,  
4 March 27-29. pp 209-214.
- 5 Drake, J., Gruntmeir, J., Merritt, H., Allen, L. and Little, S. E. (2015): False negative antigen  
6 tests in dogs infected with heartworm and placed on macrocyclic lactone preventives. *Parasit.*  
7 *Vectors*. **8**, 68.
- 8 Drake, J. and Wiseman, S. (2018): Increasing incidence of *Dirofilaria immitis* in dogs in USA  
9 with focus on the southeast region 2013-2016. *Parasit. Vectors*. **11**, 39.
- 10 Engelsberg, K. and Bläckberg, J. (2022): *Dirofilaria repens* infection of the eye. *J. Ophthalmic*  
11 *Inflamm. Infect.* **12**, 13.
- 12 ESCCAP Guideline 05 (2019): Control of vector-borne diseases in dogs and cats. Third Edition  
13 (Published in March 2019). accessed on 05/08/2021 at [www.esccap.org](http://www.esccap.org) (European Scientific  
14 Counsel Companion Animal Parasites).
- 15 ESDA Guideline 2017: Guidelines for clinical management of canine heartworm disease.  
16 Prepared for and approved by the Executive Board of ESDA.  
17 <https://www.esda.vet/media/attachments/2021/08/19/canine-heartworm-disease.pdf>
- 18 Falidas, E., Gourgiotisa, S., Ivopoulou, O., Koutsogiannis, I., Oikonomou, C., Vlachos, K. and  
19 Villias, K. (2016): Human subcutaneous dirofilariasis caused by *Dirofilaria immitis* in a Greek  
20 adult. *J. Infect. Public Health*. **9**, 102-104.
- 21 Falus, F. A., Korinna, Sz., Becker, Zs., Müller, L., Fok, É., Balogh, N. and Manczur, F. (2022):  
22 Albuminuria and proteinuria in dogs infected with *Dirofilaria repens*: a cross-sectional study.  
23 *J. Vet. Intern. Med.* (under review).
- 24 Farkas, R., Gyurkovszky, M., Lukács, Z., Aladics, B. and Solymosi, N. (2014): Seroprevalence  
25 of some vector-borne infections of dogs in Hungary. *Vector-Borne Zoonotic Dis.* **14**, 256-260.
- 26 Farkas, R. and Vörös, K. (2015): Heartworm disease in dogs. A kutyák szívférgessége. *Kamarai*  
27 *Állatorvos*. **10**, 20-31. (In Hungarian)
- 28 Farkas, R., Mag, V., Gyurkovszky, M., Takács, N., Vörös, K. and Solymosi, N. (2020): The  
29 current situation of canine dirofilariosis in Hungary. *Parasitol. Res.* **119**, 129-135.

- 1 Favia, G., Lanfrancotti, A., Della Torre, A., Cancrini, G. and Coluzzi, M. (1996): Polymerase  
2 chain reaction-identification of *Dirofilaria repens* and *Dirofilaria immitis*. Parasitology. **113**,  
3 567-571.
- 4 Fok, É., Szabó, Z. and Farkas, R. (1998): First diagnosis of *Dirofilaria repens* infection in  
5 Hungary during surgical intervention in dog. A *Dirofilaria repens* első diagnózisa  
6 Magyarországon egy kutyán végzett sebészi beavatkozás során. Kisállatorvoslás. **4**, 218-219.  
7 (In Hungarian)
- 8 Fok, É., Jacsó, O., Szebeni, Z., Gyórfy, A., Sükösd, L., Lukács, Z. and Schaper, R. (2010):  
9 Elimination of *Dirofilaria* (syn. *Nochtiella*) *repens* microfilariae in dogs with monthly  
10 treatments of moxidectin 2.5%/imidacloprid 10% (Advocate, Bayer) spot-on. Parasitol. Res.  
11 **106**, 1141-1149.
- 12 Fuehrer, H.-P., Auer, H., Leschnik, M., Silbermayr, K, Duscher, G. and Joachim, A. (2016):  
13 *Dirofilaria* in humans, dogs, and vectors in Austria (1978-2014) from imported pathogens to  
14 the endemicity of *Dirofilaria repens*. PLOS Negl. Trop. Dis. **10**, e0004547.
- 15 Fuehrer, H-P., Morelli, S., Unterköfler, M. S., Bajer, A., Bakran-Lebl, K., Dwuznik-Szarek, D.,  
16 Farkas, R., Grandi, G., Heddergott, M., Jokelainen, P., Knific, T., Leschnik, M., Miterpáková,  
17 M., Modrý, D., Petersen, H. H., Skírnisson, K., Rataj, A. V., Schnyder, M. and Strube, C.  
18 (2021): *Dirofilaria* spp. and *Angiostrongylus vasorum*: Current risk of spreading in Central and  
19 Northern Europe. Pathogens. **10**, 1268.
- 20 Garrido-Mesa, J., Algieri, F., Rodriguez-Nogales, A., Utrilla, M. P., Rodriguez-Cabezas, M. E.,  
21 Zarzuelo, A., Ocete, M. A., Garrido-Mesa, N. and Galvez, J. (2015): A new therapeutic  
22 association to manage relapsing experimental colitis: Doxycycline plus *Saccharomyces*  
23 *boulardii*. Pharmacol. Res. **97**, 48-63.
- 24 Genchi. C., Rinaldi, R., Cascone, C., Mortario, M. and Cringoli, G. (2005): Is heartworm  
25 disease really spreading in Europe? Vet. Parasitol. **133**, 137-148.
- 26 Genchi, C., Venco, L. and Genchi, M. (2007): Guideline for the laboratory diagnosis of canine  
27 and feline *Dirofilaria* infections. In: Genchi, C., Rinaldi, L., Cringoli, G. (eds.): *Dirofilaria*  
28 *immitis* and *D. repens* in Dog and Cat and Human Infections. Naples: Rolando Editore. pp. 137-  
29 144.
- 30 Genchi, C. and Kramer, L. H. (2017): Subcutaneous dirofilariosis (*Dirofilaria repens*): an  
31 infection spreading throughout the old world. Parasit. Vectors. **10**, 517.



- 1 Genchi, M., Mangia, C., Ferrari, N. and Loukeri, S. (2018): Evaluation of a rapid  
2 immunochromatographic test for the detection of low burden *Dirofilaria immitis* (heartworm)  
3 in dogs and cats. *Parasitol. Res.* **117**, 31-34.
- 4 Genchi, M., Vismarra, A., Lucchetti, C., Viglietti, A., Crosara, S., Gnudi, G., Quintavalla, C.,  
5 Schaper, R. and Kramer, L. (2019): Efficacy of imidacloprid 10%/moxidectin 2.5% spot on  
6 (Advocate®, Advantage Multi®) and doxycycline for the treatment of natural *Dirofilaria*  
7 *immitis* infections in dogs. *Vet. Parasitol.* **273**, 11-16.
- 8 Gioia, G., Lecová, L., Genchi, M., Ferri, E., Genchi, C. and Mortasino, M. (2010): Highly  
9 sensitive multiplex PCR for simultaneous detection and discrimination of *Dirofilaria immitis*  
10 and *Dirofilaria repens* in canine peripheral blood. *Vet. Parasitol.* **172**, 160–163.
- 11 Goodwin, J. K. (1998): The serologic diagnosis of heartworm infection in dogs and cats. *Clin.*  
12 *Tech. Small Anim. Pract.* **13**, 83-87.
- 13 Greene, C. E. and Calpin, J. (2012): Antimicrobial drug formulary. In: Greene, C.E. (ed.):  
14 *Infectious Diseases of the Dog and Cat*, 4<sup>th</sup> ed. St. Louis, USA: An Imprint of Elsevier Saunders.  
15 pp. 1207-1320.
- 16 Grzeskowiak, L., Endo, A., Beasley, S. and Salminen, S. (2015): Microbiota and probiotics in  
17 canine welfare. *Anaerobe.* **34**, 14-23.
- 18 Gronover, B. S. (2019): Anatomical background and ultrasound examination of the paralumbar  
19 muscles for intramuscular injection of melarsomine in canine heartworm disease. Student's  
20 scientific work (TDK), University of Veterinary Medicine Budapest.
- 21 Gruntmeir, J. M., Long, M. T., Blagburn, B. L. and Walden, H. S. (2020): Canine heartworm  
22 and preheat treatment: An evaluation using a well based enzyme-linked immunosorbent assay  
23 (ELISA) and canine sera with confirmed heartworm infection status. *Vet. Parasitol.* **283**,  
24 109169.
- 25 Härtwig, V., Dauschies, A. and Dyachenko, V. (2015): *Dirofilaria repens* infection in a dog  
26 in central Germany without any history of travel, *Tierärztl. Prax. Ausg. K Kleintiere Heimtiere.*  
27 **43**, 181-187.
- 28 Henry, L. G., Brunson, K. J., Walden, H. S., Wenzlow, N., Beachboard, S. E., Barr, K. L. and  
29 Long, M. T. (2018): Comparison of six commercial antigen kits for detection of *Dirofilaria*

1 *immitis* infections in canines with necropsy-confirmed heartworm status. *Vet. Parasitol.* **254**,  
2 178-182.

3 Hettlich, B. F., Ryan, K., Bergman, R. L., Marks, S. L., Lewis, B. C., Bahr, A., Coates, J. R.,  
4 Mansell, J. and Barton, C. L. (2003): Neurologic complications after melarsomine  
5 dihydrochloride treatment for *Dirofilaria immitis* in three dogs. *J. Am. Vet. Assoc.* **223**, 1456-  
6 1461.

7 Hoch, H. and Strickland, K. (2008a): Canine and feline dirofilariasis: life cycle,  
8 pathophysiology, and diagnosis. *Compend. Contin. Educ. Vet.* **30**, 133-140.

9 Hoch, H. and Strickland, K. (2008b): Canine and feline dirofilariasis: prophylaxis, treatment,  
10 and complications of treatment. *Compend. Contin. Educ. Vet.* **30**, 146-151.

11 Ionica, A. M., Matei, I. A., Mircean, V., Dumitrache, M. O., D'Amico, G., Györke, A.,  
12 Pantchev, N., Annoscia, G., Albrechtová, K., Otranto, D., Modrý, D. and Mihalca, A. D.,  
13 (2015): Current surveys on the prevalence and distribution of *Dirofilaria* spp. and  
14 *Acanthocheilonema reconditum* infections in dogs in Romania. *Parasitol. Res.* **114**, 975-982.

15 Jacobson, L. S. and DiGangi, B. A. (2021): An accessible alternative to melarsomine: ‘‘Moxi-  
16 doxy’’ for treatment of adult heartworm infection in dogs. *Front. Vet. Sci.* **8**, 702018.

17 Jacsó, O. (2014): Distribution of *Dirofilaria* spp. in Hungary and their veterinary importance,  
18 therapeutic experiences. PhD dissertation. Doctoral school of the University of Veterinary  
19 Medicine Budapest. (In Hungarian)

20 Jacsó O. and Fok, É. (2006): Detection of *Dirofilaria repens* infection in dogs and cats by  
21 laboratory methods. A kutyák és macskák *Dirofilaria repens* fertőzöttségének kimutatása  
22 laboratóriumi módszerekkel. *Magy. Állatorvosok Lapja.* **128**, 683–690. (In Hungarian)

23 Jacsó, O., Mándoki, M., Majoros, G., Pétsch, M., Mortarino, M., Genchi, C. and Fok, É. (2009):  
24 First autochthonous *Dirofilaria immitis* (Leidy, 1856) infection in a dog in Hungary.  
25 *Helminthologia.* **46**, 159-161.

26 Kassai, T. (2003): *Helminthológia.* Medicina Könyvkiadó, Budapest. pp. 188-192.

27 Kassai, T. (2011): *Veterinary helminthology.* Butterworth-Heinemann, Oxford (UK) and  
28 Waltham, Massachusetts (USA), pp. 121-124.

1 Keister, D. M., Tanner, P. A. and Meo, N. J. (1995): Immiticide®: Review of discovery,  
2 development, and utility. In: Soll MD, Knight DH, ds. Proceedings of the Heartworm  
3 Symposium '95. Batavia: American Heartworm Society, 201-219.

4 Kramer, L., Grandi, G., Leoni, M., Passeri, B., McCall, J., Genchi, C., Mortarino, M. and  
5 Bazzocchi, C. (2008): *Wolbachia* and its influence on the pathology and immunology of  
6 *Dirofilaria immitis* infection. Vet Parasitol **158**, 191-195.

7 Kramer, L., Grandi, G., Passeri, B., Gianelli, P., Genchi, M., Dzimianski, M. T., Supakorndej,  
8 P., Mansour, A. M., Supakorndej, N., McCall, S. D., McCall, J. W. (2011): Evaluation of lung  
9 pathology in *Dirofilaria immitis* — Experimentally infected dogs treated with doxycycline or  
10 a combination of doxycycline and ivermectin before administration of melarsomine  
11 dihydrochloride. Vet. Parasitol. **176**, 357-360.

12 Kramer, L. and Genchi, C. (2014): Where are we with *Wolbachia* and doxycycline: An in depth  
13 review of the current state of our knowledge. Vet. Parasitol. **206**, 1-4.

14 Kotlán, A. (1951): On a new case of human filarioidosis in Hungary. Acta Vet. Acad. Sci. Hung.  
15 **1**, 69-79.

16 Kozek, W. J. (2005): What is new in the *Wolbachia/Dirofilaria* interaction? Vet Parasitol **133**,  
17 1278-1232.

18 Laidoudi, Y., Otranto, D., Stolowy, N., Amrane, S., Manoj, R. R. S., Polette, L., Watier-Grillot,  
19 S., Mediannikov, O., Davoust, B. and L'Ollivier, C. (2021): Human and animal dirofilariasis in  
20 Southeast of France. Microorganisms. **9**, 1544.

21 Lane, J.N., Litster, A., Little, S. E., Rodriguez, J. Y., Mwacalimba, K. K., Sundstrom, K. D,  
22 Amirian, E. S., Guerios, S. D., Serrano, M. A., Hays, K. M. and Levy, J. K. (2021) Optimizing  
23 heartworm diagnosis in dogs using multiple test combinations. Parasites Vectors. **14**:224.

24 Latrofa, M. S., Dantas-Torres, F., Annoscia, G., Genchi, M., Traversa, D. and Otranto, D.  
25 (2012): A duplex real-time polymerase chain reaction assay for the detection of and  
26 differentiation between *Dirofilaria immitis* and *Dirofilaria repens* in dogs and mosquitoes. Vet.  
27 Parasitol. **185**, 181-185.

28 Le Sueur, C., Bour, S. and Schaper, R. (2010): Efficacy of a combination of imidacloprid  
29 10%/moxidectin 2.5% spot-on (Advocate® for dogs) in the prevention of canine spirocercosis  
30 (*Spirocerca lupi*). Parasitol. Res. **107**, 1463-1469.

- 1 Lee, A. C., Bowman, D. D., Lucio-Forster, A., Beall, M. J., Liotta, J. L. and Dillon, R. (2011):  
2 Evaluation of a new in-clinic method for the detection of canine heartworm antigen. Short  
3 communication. *Vet. Parasitol.* **177**, 387-391.
- 4 Lombard, C. W. and Ackerman, N. (1984): Right heart enlargement in heartworm infected  
5 dogs. A radiographic, electrocardiographic, and echocardiographic correlation. *Vet. Radiol.* **25**,  
6 210-217.
- 7 Losonsky, J.M., Thrall, D. E. and Lewis, R. E. (1983): Thoracic radiographic abnormalities in  
8 200 dogs with heartworm infestation. *Vet. Radiol.* **24**, 120-123.
- 9 Liu, J., Song, K. H., Lee, S. E., Lee, J. Y., Lee, J. I., Hayasaki, M., You, M. J. and Kim, D. H.  
10 (2005): Serological and molecular survey of *Dirofilaria immitis* infection in stray cats in  
11 Gyunggi province, South Korea, *Vet. Parasitol.* **130**, 125-129.
- 12 Magnis, J., Lorentz, S., Guardone, L., Grimm, F., Magi, M., Naucke, T. J. and Deplazes, P.  
13 (2013): Morphometric analyses of canine blood microfilariae isolated by the Knott's test  
14 enables *Dirofilaria immitis* and *D. repens* species-specific and *Acanthocheilonema* (syn.  
15 *Dipetalonema*) genus-specific diagnosis. *Parasit. Vectors.* **6**, 48.
- 16 Majoros, G., Fukár, O. and Farkas, R. (2010): Autochthonous infection of dogs and slugs with  
17 *Angiostrongylus vasorum* in Hungary. Short communication. *Vet. Parasitol.* **174**, 351-354.
- 18 Majoros, G. and Juhász, A. (2015a): Investigation of microfilariae of *Dirofilaria immitis* and  
19 *Dirofilaria repens* by light microscope. Part 1: Recognition of microfilariae in different  
20 samples. A *Dirofilaria immitis* és *Dirofilaria repens* mikrofiláriák fénymikroszkópos vizsgálata  
21 1. rész: A mikrofiláriák felismerése a különféle mintákban. *Magy. Állatorvosok Lapja.* **137**,  
22 173-180. (In Hungarian)
- 23 Majoros G. and Juhász A. (2015b): Investigation of microfilariae of *Dirofilaria immitis* and  
24 *Dirofilaria repens* by light microscope Part 2: Identification of *Dirofilaria* species by  
25 morphology of microfilariae. A *Dirofilaria immitis* és *Dirofilaria repens* mikrofiláriák  
26 fénymikroszkópos vizsgálata 2. rész: A *Dirofilaria*-fajok azonosítása a mikrofiláriák  
27 segítségével. *Magy. Állatorvosok Lapja.* **137**, 227-238. (In Hungarian)
- 28 Malik, D., Amaraneni, A., Singh, S., Roach, R. (2016): Man's best friend: How humans can  
29 develop *Dirofilaria immitis* infections. *IDCases.* **4**, 43-45.

- 1 Manfredi, M. T., Vieira, C., Bandi, C., Casiraghi, M. and Simón, F. (2001): Phylogeny,  
2 systematics and structural aspects, in: Simón, F. and Genchi, C. (eds.), Heartworm Infection in  
3 Humans and Animals. Ediciones Universidad de Salamanca. Salamanca, pp. 23-26.
- 4 Manfredi, M. T., Di Cerbo, A. and Genchi M. (2007): Biology of filarial worms parasitizing  
5 dogs and cats, In: Genchi, C., Rinaldi, L. and Cringoli, G. (eds.), *Mappe Parassitologiche* 8.  
6 Rolando Editore, Naples, pp. 41-45.
- 7 Matic, S. E. and Herrtage, M. E. (1987): Diagnosis and treatment of occult dirofilariosis in an  
8 imported dog. *J. Small Anim. Pract.* **28**, 183-196.
- 9 Maxwell, E., Ryan, K., Reynolds, C. and Pariaut, R. (2014): Outcome of a heartworm treatment  
10 protocol in dogs presenting to Louisiana State University from 2008 to 2011: 50 cases. *Vet.*  
11 *Parasitol.* **206**, 71-77.
- 12 McCall, J. W., Genchi, C., Kramer, L. H., Guerrero, J. and Venco, L. (2008): Heartworm  
13 disease in animals and humans, *Adv. Parasitol.* **66**, 193-285.
- 14 McCall, J. W., Artherb, R., Davis, W. and Settje, T. (2014): Safety and efficacy of 10%  
15 imidacloprid +2.5% moxidectin for the treatment of *Dirofilaria immitis* circulating  
16 microfilariae in experimentally infected dogs. *Vet. Parasitol.* **206**, 86-92.
- 17 Mendoza-Roldan, J. A., Gabriella, S., Cascio, A., Manoj, R. R. S., Bezerra-Santos, M. A,  
18 Benelli, G., Brianti, E., Latrofa, M. S. and Otranto, D. (2021): Zoonotic *Dirofilaria immitis* and  
19 *Dirofilaria repens* infection in humans and an integrative approach to the diagnosis. *Acta*  
20 *Tropica.* **223**, 106083.
- 21 Merial Limited Immiticide®. Duluth, Georgia: Merial, Inc. 2010. Available at  
22 <https://www.drugs.com/pro/immiticide.html>
- 23 Miterpáková, M., Antolová, D., Rampalová, J., Undesser, M., Krajčovič, T. and Víchová, B.  
24 (2022): *Dirofilaria immitis* pulmonary dirofilariosis, Slovakia. *Emerg. Infect. Dis.* **28**, 482-485.
- 25 Moore, S. A., Mariani, C. L., Van Wettere, A. and Borst, L. B. (2013): Chronic compressive  
26 myelopathy and progressive neurologic signs associated with melarsomine dihydrochloride  
27 administration in a dog. *J. Am. Anim. Hosp. Assoc.* **49**, 389-393.
- 28 Morchón, R., Carretón, E., González-Miguel, J. and Mellado-Hernández, I. (2012a):  
29 Heartworm disease (*Dirofilaria immitis*) and their vectors in Europe – new distribution trends.  
30 Review article. *Front. Physiol.* **3**, 196.

1 Morchón, R., Carretón, E., Grandi, G., Gonzalez-Miguel, J., Montoya-Alonso, J. A., Simón, F.,  
2 Genchi, C. and Kramer, L. H. (2012b): Anti-*Wolbachia* surface protein antibodies are present  
3 in the urine of dogs naturally infected with *Dirofilaria immitis* with circulating microfilariae  
4 but not in dogs with occult infections, Vector Borne Zoonotic Dis. **12**, 17-20.

5 Morchón, R., Montoya-Alonso, J. A., Rodríguez-Escolar, I. and Carreton, E. (2022): What has  
6 happened to heartworm disease in Europe in the last 10 years? Pathogens, **11**, 1042.

7 Nelson, C. T. (2012): Heartworm disease. In: Greene, C. E. (ed.): Infectious Diseases of the  
8 Dog and Cat, 4th ed. St. Louis, USA: An Imprint of Elsevier Saunders. pp. 865-877.

9 Nelson, C. T., McCall, J. W., Jones, S. and Moorhead, A. (eds.) (2014): Current canine  
10 guidelines for the prevention, diagnosis, and management of heartworm (*Dirofilaria immitis*)  
11 infection in dogs (revised July 2014). <http://www.heartwormsociety.org>

12 Nelson, T. C., McCall, J. W., Jones, S. and Moorhead, A. (eds.) (2018): Prevention, Diagnosis,  
13 and Management of Heartworm Infection in Dogs, 2018.  
14 [www.heartwormsociety.org/veterinaryresources/american-heartworm-society-guidelines](http://www.heartwormsociety.org/veterinaryresources/american-heartworm-society-guidelines).  
15 accessed on 18/09/2018 at <http://www.heartwormsociety.org>

16 Nelson, T. C., McCall, J. W., Jones, S. and Moorhead, A. (eds.) (2020): Current canine  
17 guidelines for the prevention, diagnosis, and management of heartworm (*Dirofilaria immitis*)  
18 infection in dogs (reviewed and updated 11-13-20), 2020. accessed on 08/05/2021  
19 at <http://www.heartwormsociety.org>

20 Nelson, C. T., Myrick, E. S. and Nelson, T. A. (2017): Clinical benefits of incorporating  
21 doxycycline into a canine heartworm treatment protocol. Parasit. Vectors. **7**, 515.

22 Nemes, Cs., Császár, L., Turbók, J., Simonyai, E., Csivincsik, Á. and Nagy, G. (2016): Perish  
23 caused by French heartworm infection in a Hungarian dog. Case report. *Angiostrongylus*  
24 *vasorum* fertőzöttség okozta elhullás magyarországi kutyában. Magy. Állatorvosok Lapja, **138**,  
25 613-619. (In Hungarian)

26 Niwetpathomwat, A., Kaewtharmasorn, M., Tiawsirisup, S., Techangamsuwan, S. and  
27 Suvarnvibhaja, S. (2007): A retrospective study of the clinical hematology and the serum  
28 biochemistry tests made on canine dirofilariasis cases in an animal hospital population in  
29 Bangkok, Thailand. Res. Vet. Sci. **82**, 364-369.

1 Paes-de-Almeida, E. C., Ferreira, A. M. R., Labarthe, N. V., Caldas, M. L. R. and McCall, J.  
2 W. (2003): Kidney ultrastructural lesions in dogs experimentally infected with *Dirofilaria*  
3 *immitis* (Leidy, 1856). Vet. Parasitol. **113**, 157-168.

4 Pampiglione, S., Canestri Trotti, G. and Rivasi, F. (1995): Human dirofilariasis due to  
5 *Dirofilaria (Nochtiella) repens*: a review of world literature. Parasitologia. **37**, 149-193.

6 Parsa, R., Sedighi, A., Sharifi, I., Bamorovat, M. and Nasibi, S. (2020): Molecular  
7 characterization of ocular dirofilariasis: a case report of *Dirofilaria immitis* in south-eastern  
8 Iran. BMC Inf. Dis. **20**, 520.

9 Pariaut, R., Jung, S. W., Vila, J. and Newhard, D. H. (2020): Resolution of caval syndrome  
10 during initial hemodynamic stabilization in dogs with heartworm disease. J. Vet. Emerg. Crit.  
11 Care. **30**, 295-301.

12 Preyß-Jägeler, C., Hatrmann, K. and Dorsch, R. (2022): Role of systemic infections in canine  
13 kidney diseases. Tierärztl. Prax. Ausg. K Kleintiere Heimtiere. **50**, 124-136.

14 Psáder, R., Balogh, M., Pápa, K., Sterczer, Á., Lukács, Z and Harnos, A (2017): Occurrence  
15 of *Spirocerca lupi* infection in Hungarian dogs referred for gastroscopy. Parasitol. Res. **116**,  
16 99-108.

17 Rawlings, C. A., Dawe, D. L., McCall, J. W., Keith, J. C. and Prestwood, A. K. (1982): Four  
18 types of occult *Dirofilaria immitis* infection in dogs. J. Am. Vet. Med. Assoc. **180**, 1323-1326.

19 Rawlings, C. A., Losonsky, J. M., Schaub, R. G., Greene, C. E., Keith, J. C. and McCall, J. W.  
20 (1983): Postadulthood changes in *Dirofilaria immitis*-infected beagles. Am. J. Vet. Res. **44**, 8-  
21 15.

22 Rawlings, C. A. (1986): Heartworm disease in dogs and cats. W B Saunders Co, Philadelphia,  
23 USA.

24 Rishniw, M., Barr, S. C., Simpson, K. W., Frongillo, M. F., Franz, M., and Dominguez Alpizar,  
25 J. L. (2006): Discrimination between six species of canine microfilariae by a single polymerase  
26 chain reaction. Vet. Parasitol. **135**, 303-314.

27 Rojas, A., Rojas D., Montenegro, V. M. and Baneth, G. (2015): Detection of *Dirofilaria immitis*  
28 and other arthropod-borne filarioids by an HRM real-time qPCR, blood-concentrating  
29 techniques and a serological assay in dogs from Costa Rica. Parasit. Vectors. **8**, 170.

- 1 Roth, L., Brown, L., Brum, S., Nelson, L. F. M., Reczeck, D. and von Schantz, D. (1993):  
2 Comparison of three diagnostic tests for *Dirofilaria immitis* in a low-incidence area. J. Vet.  
3 Diagn. Investig. **5**, 647-648.
- 4 Savadelis, M. D., Ohmes, C. M., Hostetler, J. A., Settje, T. L., Zolynas, R., Dzimianski, M. T.  
5 and Moorhead, A. R. (2017): Assessment of parasitological findings in heartworm-infected  
6 beagles treated with Advantage Multi® for dogs (10% imidacloprid + 2.5% moxidectin) and  
7 doxycycline. Parasit. Vectors **10**, 245.
- 8 Savadelis, M. D., Roveto, J. L., Ohmes, C. M., Hostetler, J. A., Settje, T. L., Dzimianski, M. T.  
9 and Moorhead, A. R. (2018): Evaluation of heat-treating heartworm-positive canine serum  
10 samples during treatment with Advantage Multi® for Dogs and doxycycline. Parasit. Vectors  
11 **11**, 98.
- 12 Schmitz, S. S. (2021): Value of probiotics in canine and feline gastroenterology. Review article.  
13 Vet. Clin. North Am. Small Anim. Pract. Med. **51**, 171-217.
- 14 Schulz, B. S., Hupfauer, H., Ammer, H., Sauter-Louis, C. and Hartmann, K. (2011): Suspected  
15 side effects of doxycycline use in dogs - A retrospective study of 386 cases. Vet. Rec. **169**, 229.
- 16 Schnyder, M. and Deplazes, P. (2012): Cross-reactions of sera from dogs infected with  
17 *Angiostrongylus vasorum* in commercially available *Dirofilaria immitis* test kits. Parasit.  
18 Vectors. **13**, 258.
- 19 Schnyder, M., Schaper, R., Lukács, Z., Hornok, S. and Farkas, R. (2015): Combined serological  
20 detection of circulating *Angiostrongylus vasorum* antigen and parasite-specific antibodies in  
21 dogs from Hungary. Parasitol. Res. **114**, 139-148.
- 22 Shah, M. P., Gujjari, S. K. and Chandrasekhar, V. (2013): Evaluation of the effect of probiotic  
23 (Inersan®) alone, combination of probiotic with doxycycline and doxycycline alone on  
24 aggressive periodontitis - A clinical and microbiological study. J. Clin. Diagn. Res. **7**, 595-600.
- 25 Simón, F., Siles-Lucas, M., Morchón, R., González-Miguel, J., Mellado, I., Carretón, E. and  
26 Montoya-Alonso, J. A. (2012): Human and animal dirofilariasis: the emergence of a zoonotic  
27 mosaic. Clin. Microbiol. Rev. **25**, 507-544.
- 28 Sobotyck, C., Savadelis, M. D. and Verocai, G. G. (2021): Detection and cross-reaction of  
29 *Dirofilaria repens* using a commercial heartworm antigen test kit. Vet. Parasitol. **289**, 109302.



- 1 Spasojevic Kotic, L., Lalosevic, V., Lalosevic, D., Stanislav, S., Vasic, I. and Kuruca, L.  
2 (2012): Prevalence of dirofilariosis in pet dogs in Novi Sad. *Contemp. Agric.* **61**, 247-254.
- 3 Starkey, L. A., Bowles, J. V., Payton, M. E. and Blagburn, B. L. (2017): Comparative  
4 evaluation of commercially available point-of-care heartworm antigen tests using well-  
5 characterized canine plasma samples. *Parasit. Vectors* **10**, 475.
- 6 Stevenson, M. (2008): An introduction to veterinary epidemiology.  
7 [http://www.massey.ac.nz/massey/fms/Colleges/College%20of%20Sciences/Epicenter/docs/A](http://www.massey.ac.nz/massey/fms/Colleges/College%20of%20Sciences/Epicenter/docs/SVCS/Stevenson_intro_epidemiology-web_2008.pdf)  
8 [SVCS/Stevenson\\_intro\\_epidemiology-web\\_2008.pdf](http://www.massey.ac.nz/massey/fms/Colleges/College%20of%20Sciences/Epicenter/docs/SVCS/Stevenson_intro_epidemiology-web_2008.pdf)
- 9 Szatmári, V. (2020): False positive antigen test for *Dirofilaria immitis* after preheat treatment  
10 of the blood sample in a microfilaremic dog infected with *Acanthocheilonema dracunculoides*.  
11 *Parasit. Vectors* **13**, 501.
- 12 Széll, Z., Máthé, Á., Erdélyi, I., Deim, Z., Bende, Z., and Varga, I. (2001): Spirocercosis and  
13 alariosis – two rare helminthosis in dogs. Brief review and two case reports. Spirocercosis és  
14 alariosis – két ritka helminthosis kutyákban. Rövid irodalmi áttekintés és két eset ismertetése.  
15 *Magy. Állatorvosok Lapja* **123**, 421-428. (In Hungarian)
- 16 Széll, Z., Sréter, T., Csikós, K., Kátai, Z., Dobos-Kovács, M., Vetési, F. and Varga, I. (1999):  
17 Autochthon *Dirofilaria repens* infection in dogs. Autochthon *Dirofilaria repens* fertőzöttség  
18 kutyában. *Magy. Állatorvosok Lapja*. **121**, 100-104. (In Hungarian)
- 19 Tarello, W. (2011): Clinical Aspects of dermatitis associated with *Dirofilaria repens* in pets: A  
20 review of 100 canine and 31 feline cases (1990-2010) and a report of a new clinic case imported  
21 from Italy to Dubai. *J. Parasitol. Res.* **2011**, 578385.
- 22 Thomason, J. D. and Calvert, C. A. (2015): Heartworm disease. in: Smith, F. W. K., Tilley, L.  
23 P., Oyama, M. and Sleeper, M. M. (eds.): *Manual of canine and feline cardiology*. 5th ed.  
24 Elsevier, St. Luis, 2015. pp. 188–197.
- 25 Thrall, D. E. and Calvert, C. A. (1983): Radiographic evaluation of canine heartworm disease  
26 coexisting with right heart failure. *Vet. Radiol.* **24**, 124-126.
- 27 Tjostheim, S. S., Kelliham, H. B., Grint, K. A. and Stepien, R. L. (2019): Effect of sildenafil  
28 and pimobendan on intracardiac heartworm infections in four dogs. *J. Vet. Cardiol.* **23**, 96-103.

- 1 Tolnai, Z., Széll, Z., Sproch, Á., Szeredi, L. and Sréter, T. (2014): *Dirofilaria immitis*: an  
2 emerging parasite in dogs, red foxes and golden jackals in Hungary. *Vet. Parasitol.* **203**, 339-  
3 342.
- 4 Trájer, A., Rengei, A., Farkas-Iványi, K. and Bede-Fazekas, Á. (2016): Impacts of urbanisation  
5 level and distance from potential natural mosquito breeding habitats on the abundance of canine  
6 dirofilariosis. *Acta Vet. Hung.* **64**, 340-359.
- 7 Túri Á. and Hettyey, Cs. (2014): First report of *Dirofilaria immitis* in the arteria pulmonalis in  
8 Hungary, imaged by ultrasonography. *Dirofilaria immitis* első magyarországi kimutatása a  
9 tüdőartériában echokardiográfiás vizsgálattal. *Magy. Állatorvosok Lapja.* **136**, 231-233. (In  
10 Hungarian)
- 11 Van Zeeland, Y. R. A. and Schoemaker, N. J. (2022): Ferret cardiology. *Vet. Clin. Exot.*  
12 *Anim. Pract.* **25**, 541-562.
- 13 Velasquez, L., Blagburn, B. L., Duncan-Decoq, R., Johnson, E. M., Allen, K. E., Meinkoth, J.,  
14 Gruntmeir, J. and Little, S. E. (2014): Increased prevalence of *Dirofilaria immitis* antigen in  
15 canine samples after preheat treatment. *Vet. Parasitol.* **206**, 67-70.
- 16 Venco, L., Genchi, C., Vigevani Colson, P. and Kramer, L. (2003) Relative utility of  
17 echocardiography, radiography, serologic testing and microfilariae counts to predict adult  
18 worm burden in dogs naturally infected with heartworms. In: Seward, R. L. and Knight, D. H.  
19 (eds.) *Recent Advances in Heartworm Disease, Symposium'01*. American Heartworm Society,  
20 Batavia, IL, 2003. pp. 111-124.
- 21 Venco, L., Manzocchi, S., Genchi, M. and Kramer, L. H. (2017): Preheat treatment and false-  
22 positive heartworm antigen testing in ex vivo parasites and dogs naturally infected by  
23 *Dirofilaria repens* and *Angiostrongylus vasorum*. *Parasit. Vectors* **10**, 476.
- 24 *Vin Veterinary Drug Handbook.*  
25 <https://www.vin.com/members/cms/project/defaultadv1.aspx?pid=13468>
- 26 Vörös, K., Kiss, G., Baska, F., Bagdi, N. and Széll, Z. (2000): Heartworm disease in a dog.  
27 Review article and case report. *Szívférgesség kutyában. Irodalmi áttekintés és esetismertetés.*  
28 *Magy. Állatorvosok Lapja.* **122**, 707-716. (in Hungarian)
- 29 Vörös, K., Becker, Zs., Arany-Tóth, A., Gyurkovszky M. and Farkas, R. (2017): Occult *D.*  
30 *immitis* heartworm disease in a dog. Case report and literature review. *Okkult Dirofilaria*

1 *immitis* szívférgesség kutyában. Esetismertetés és irodalmi áttekintés. Magy. Állatorvosok  
2 Lapja. **139**, 675-685. (In Hungarian)

3 Vörös, K. (2019): Szívférgesség. In: Vörös, K. (ed.) Állatorvosi belgyógyászat. A kutyák és a  
4 macskák betegségei. MÁOK Kft., Budapest. pp. 334-347.

5 Vörös, K., Becker, Zs., Dudás-Györki, Z., Gronover, B.S. and Szalay F. (2022a):  
6 Ultrasonography of the paralumbar muscles as a new aid during melarsomine treatment in  
7 canine heartworm disease. Acta Vet. Hung. **70**, 263-268.

8 Vörös, K., Becker, Zs., Kónya, R., Arany-Tóth, A. and Farkas, R. (2022b): Application of  
9 moxidectin and ultrasound-aided injection of melarsomine during the American Heartworm  
10 Society recommended treatment protocol in *Dirofilaria immitis* infected dogs. Vector Borne  
11 Zoonotic Dis. **22**, 382-390.

12 Ware, A. (2014): Heartworm disease. In Nelson, R. W. and Couto, C. G. (eds.): Small animal  
13 Internal medicine. 5th ed. Mosby, St. Luis. 173–189.

14 Ware, W. A. and Ward, J. L. (2020) Pulmonary hypertension and heartworm disease. In:  
15 Nelson, R. W. and Couto, C. G. (eds.): Small animal internal medicine. 6th ed. Elsevier, St.  
16 Luis. pp 190–210.

17 Wylęgała, A., Wróblewska-Czajka, E. and Wylęgała, E. (2022): Subconjunctival dirofilariasis.  
18 Am. J. Ophthalmol. **233**, E1.

19 Wong, M. M. Suter, P. F, Rhode, E. A. and Guest, M. F. (1973): Dirofilariasis without  
20 circulating microfilariae: A problem in diagnosis. J. Am. Vet. Med. Assoc. **163**, 133-139.

21 Yoon. W-K., Choi, R., Lee, S. G. and Hyun, C. (2013): Comparison of 2 retrieval devices for  
22 heartworm removal in 52 dogs with heavy worm burden. J. Vet. Intern. Med. **27**, 469-473.

23 Zimmermann, P. and Curtis, N. (2019): The effect of antibiotics on the composition of the  
24 intestinal microbiota - A systematic review. J. Infect. **79**, 471-489.

25 Zoetis Inc., Diroban® 2020: Zoetis Inc. Diroban® [package insert], Zoetis inc., Kalamzoo  
26 Michigan, USA, Diroban®. [https://www.zoetisus.com/products/dogs/diroban/  
27 resources/diroban-prescribing-information.pdf](https://www.zoetisus.com/products/dogs/diroban/resources/diroban-prescribing-information.pdf)

28

29

## 1 **The author's scientific publications**

### 2 *Publications as the basis of the thesis*

3 **Becker, Zs.**, Holló, N., Farkas, R., Gyurkovszky, M., Reiczigel, J., Olaszy, K., Vári, Z. and  
4 Vörös, K. (2022a): Serodiagnostic difficulties and possibilities of heartworm disease in regions  
5 where both *Dirofilaria immitis* and *Dirofilaria repens* infections occur. Acta Vet. Hung. **70**, 92-  
6 99.

7 **Becker, Zs.**, Vörös, K., Arany-Tóth, A. and Jerzsele, Á. (2022b): Clinical characteristics and  
8 treatment of severe heartworm disease in dogs. Literature review and own experiences. Magy.  
9 Állatorvosok Lapja. **144**, 473-492.

10 Vörös, K., **Becker, Zs.**, Arany-Tóth, A., Gyurkovszky, M. and Farkas R. (2017): Okkult  
11 *Dirofilaria immitis* szívférgesség kutyában. Esetismertetés és irodalmi áttekintés. (Occult *D.*  
12 *immitis* heartworm disease in a dog. Case report and literature review.) Magy. Állatorvosok  
13 Lapja. **139**, 675-685.

14 Vörös, K., **Becker, Zs.**, Dudás-Györki, Z., Gronover, B.S. and Szalay F. (2022a):  
15 Ultrasonography of the paralumbar muscles as a new aid during melarsomine treatment in  
16 canine heartworm disease. Acta Vet. Hung. **70**, 263-268.

17 Vörös, K., **Becker, Zs.**, Kónya, R., Arany-Tóth, A. and Farkas, R. (2022b): Application of  
18 moxidectin and ultrasound-aided injection of melarsomine during the American Heartworm  
19 Society recommended treatment protocol in *Dirofilaria immitis* infected dogs. Vector Borne  
20 Zoonotic Dis. **22**, 382-390.

### 21 *Other publications of the author*

22 Falus, F. A., Korinna, Sz., **Becker, Zs.**, Müller, L., Fok, É., Balogh, N. and Manczur, F. (2022):  
23 Albuminuria and proteinuria in dogs infected with *Dirofilaria repens*: a cross-sectional study.  
24 J. Vet. Intern. Med. (under review).

25 **Becker, Zs.**, Vörös, K., Dudás-Györki, Z., Gyurkovszky, M. and Farkas, R.: Complex therapy  
26 of heartworm disease in dogs: preliminary experiences. Annual Conference of the Veterinary  
27 Scientific Committee of the Hungarian Academy of Science, 2018, Budapest.

28 **Becker, Zs.**, Vörös, K., Holló, N., Dudás-Györki, Z., Reiczigel, J. Takács, N. and Farkas, R.:  
29 Sensitivity and specificity of Vetscan Ag-test in the individual or mixed infection of *D. immitis*

- 1 and *D. repens* in dogs. Annual Conference of the Veterinary Scientific Committee of the  
2 Hungarian Academy of Science, 2019, Budapest.
- 3 Szalay, F., Vörös, K., Gronover, B. S., **Becker**, Zs., Dudás-Györki, Z.: Anatomic and  
4 ultrasonographic examination of the paralumbar musculature after the application of  
5 melarsomine during the treatment of canine heartworm disease. Annual Conference of the  
6 Veterinary Scientific Committee of the Hungarian Academy of Science, 2020, Budapest.

## 1 **Acknowledgements**

2 I wish to express my special thanks to my supervisors, Prof. Károly Vörös and Prof. Róbert  
3 Farkas for their advice and constant help during the whole PhD course. I also express my special  
4 thanks to the head of the Department and Clinic of Internal Medicine, Dr. Ferenc Manczur for  
5 supporting this research.

6 I would like to extend my thanks to my colleagues at the Diagnostic imaging division of our  
7 department (Dr. Csaba Hetey, Dr. Zoltán Dudás-Györki, Dr. Gergely Kiss, Dr. Márton Boros,  
8 Dr. Roland Psáder and Dr. Márton Balogh), also at the Radiology division of the Department  
9 and Clinic of Surgery and Ophthalmology (Dr. Attila Arany-Tóth and Dr. Péter Molnár). I  
10 express my special thanks to the staff, who performed the parasitological laboratory  
11 examinations: Mónika Gyurkovszky and Nóra Takács (Department of Parasitology and  
12 Zoology), the Department of Pathophysiology and Oncology and Laboratory, the PraxisLab  
13 kft. and the Vet-Med-Labor Zrt. I am also thankful to my co-authors (whom I did not listed  
14 earlier) i.e., Bernd Schulze Gronover, Ákos Jerzsele, Krisztián Olaszy, Jenő Reiczigel, and  
15 Zoltán Vári. This thesis could not be formed without the help of the colleagues and assistants  
16 at the Small Animal Clinic of the University of Veterinary Medicine Budapest.

17 Two TDK theses were supervised by me, and I would like to thank to my former earlier  
18 supervised students, Dr. Noémi Holló and Dr. Réka Kónya for their help and contribution.

19 Finally, I would like to express my thanks to my family and friends, who supported me during  
20 the whole time.

21 This PhD thesis was supported financially by the Doctoral School of UVMB. Further financial  
22 sources were received through the following scientific founs of UVMB: KK 69P02RM06  
23 (2017) and NKB (2018).

24